Revance Therapeutics (RVNC) S-4 9 Jun 20 Registration of securities issued in business combination transactions Financial data

Cover Page

Cover Page	3 Months Ended
	Mar. 31, 2020
Cover [Abstract]
Document Type	S-4
Entity Registrant Name	Revance Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0551645
Entity Address, Address Line One	7555 Gateway Boulevard
Entity Address, City or Town	Newark
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94560
City Area Code	510
Local Phone Number	742-3400
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Central Index Key	0001479290
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 286,649	$ 171,160	$ 73,256
Short-term investments	224,621	118,955	102,556
Accounts and other receivables		0	27,000
Prepaid expenses and other current assets	7,171	6,487	5,110
Total current assets	518,441	296,602	207,922
Property and equipment, net	13,967	14,755	14,449
Intangible assets	32,334	0
Operating lease right of use assets	25,961	26,531	0
Restricted cash	730	730	730
Other non-current assets	1,494	1,669	3,247
TOTAL ASSETS	592,927	340,287	226,348
CURRENT LIABILITIES
Accounts payable	8,709	8,010	8,434
Accruals and other current liabilities	16,178	18,636	14,948
Deferred revenue, current portion	10,079	7,911	8,588
Operating lease liabilities, current portion	3,627	3,470	0
Derivative liability, current	3,042	2,952	0
Total current liabilities	41,635	40,979	31,970
Convertible senior notes	171,305	0
Deferred revenue, net of current portion	46,722	47,948	42,684
Operating lease liabilities, net of current portion	24,890	25,870	0
Deferred rent			3,319
Derivative liability, non-current		0	2,753
TOTAL LIABILITIES	284,552	114,797	80,726
Commitments and Contingencies
STOCKHOLDERS’ EQUITY
Convertible preferred stock, value	0	0	0
Common stock, value	57	52	37
Additional paid-in capital	1,213,931	1,069,639	830,368
Accumulated other comprehensive income (loss)	524	3	(8)
Accumulated deficit	(906,137)	(844,204)	(684,775)
TOTAL STOCKHOLDERS’ EQUITY	308,375	225,490	145,622
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 592,927	$ 340,287	$ 226,348

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Convertible preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock authorized (shares)	5,000,000	5,000,000	5,000,000
Convertible preferred stock issued (shares)	0	0	0
Convertible preferred stock outstanding (shares)	0	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	95,000,000	95,000,000	95,000,000
Common stock, shares issued (in shares)	57,026,154	52,374,735	36,975,203
Common stock, shares outstanding (in shares)	57,026,154	52,374,735	36,975,203

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 58	$ 278	$ 413	$ 3,729	$ 262
Operating expenses:
Research and development	39,794	23,995	102,861	92,500	80,361
Selling, general and administrative	21,224	12,910	62,011	53,863	37,398
Loss on impairment			0	0	2,927
Total operating expenses	61,018	36,905	164,872	146,363	120,686
Loss from operations	(60,960)	(36,627)	(164,459)	(142,634)	(120,424)
Interest income	1,491	1,570	5,532	4,023	1,410
Interest expense	(2,148)	0	0	(44)	(457)
Changes in fair value of derivative liability	(90)	(92)	(199)	(140)	(591)
Other expense, net	(126)	(155)	(303)	(773)	(525)
Loss before income taxes	(61,833)	(35,304)	(159,429)	(139,568)	(120,587)
Income tax provision	(100)	0	0	(3,000)	0
Net loss	(61,933)	(35,304)	(159,429)	(142,568)	(120,587)
Unrealized gain (loss) and adjustment on securities included in net loss	521	78	11	(8)	45
Comprehensive loss	(61,412)	(35,226)	(159,418)	(142,576)	(120,542)
Basic and diluted net loss	$ (61,933)	$ (35,304)	$ (159,429)	$ (142,568)	$ (120,587)
Basic and diluted net loss per share (in dollars per share)	$ (1.15)	$ (0.85)	$ (3.67)	$ (3.94)	$ (4.01)
Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)	53,868,036	41,598,919	43,460,804	36,171,582	30,101,125

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Other Accumulated Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance (in shares) at Dec. 31, 2016		28,648,954
Beginning Balance at Dec. 31, 2016	$ 177,071	$ 29	$ 598,630	$ (45)	$ (421,543)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net settlement of restricted stock awards for employee taxes | Accounting Standards Update 2016-09			37		(37)
Issuance of common stock relating to employee stock purchase plan (in shares)		28,135
Issuance of common stock relating to employee stock purchase plan	583		583
Stock-based compensation expense	13,230		13,230
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)		1,802,651
Issuance of common stock in connection with At-The-Market offering, net of issuance costs	38,157	$ 2	38,155
Issuance of common stock in connection with the follow on offering, net of issuance costs (in shares)		5,389,515
Issuance of common stock in connection with the follow on offering, net of issuance costs	$ 156,933	$ 5	156,928
Issuance of common stock upon net exercise of warrant (in shares)		9,878
Issuance of common stock upon exercise of stock options and warrants (in shares)	309,341	309,341
Issuance of common stock upon exercise of stock options and warrants	$ 3,986	$ 1	3,985
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)		353,620
Net settlement of restricted stock awards for employee taxes (in shares)		(26,019)
Net settlement of restricted stock awards for employee taxes	(573)		(573)
Unrealized gain (loss) and adjustment on securities included in net loss	45			45
Net loss	(120,587)				(120,587)
Ending Balance (in shares) at Dec. 31, 2017		36,516,075
Ending Balance at Dec. 31, 2017	268,845	$ 37	810,975	0	(542,167)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net settlement of restricted stock awards for employee taxes | Accounting Standards Update 2018-07			40		(40)
Issuance of common stock relating to employee stock purchase plan (in shares)		37,894
Issuance of common stock relating to employee stock purchase plan	765		765
Stock-based compensation expense	$ 16,273		16,273
Issuance of common stock upon exercise of stock options and warrants (in shares)	293,100	293,100
Issuance of common stock upon exercise of stock options and warrants	$ 4,527		4,527
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)		201,032
Net settlement of restricted stock awards for employee taxes (in shares)		(72,898)
Net settlement of restricted stock awards for employee taxes	(2,212)		(2,212)
Unrealized gain (loss) and adjustment on securities included in net loss	(8)			(8)
Net loss	$ (142,568)				(142,568)
Ending Balance (in shares) at Dec. 31, 2018	36,975,203	36,975,203
Ending Balance at Dec. 31, 2018	$ 145,622	$ 37	830,368	(8)	(684,775)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense			4,159
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)		6,764,705
Issuance of common stock in connection with At-The-Market offering, net of issuance costs		$ 7	107,572
Issuance of common stock upon exercise of stock options and warrants (in shares)		2,824
Issuance of common stock upon exercise of stock options and warrants			18
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)		323,026
Net settlement of restricted stock awards for employee taxes (in shares)		(61,100)
Net settlement of restricted stock awards for employee taxes			(1,049)
Unrealized gain (loss) and adjustment on securities included in net loss	78			78
Net loss	$ (35,304)				(35,304)
Ending Balance (in shares) at Mar. 31, 2019	44,004,658	44,004,658
Ending Balance at Mar. 31, 2019	$ 221,103	$ 44	941,068	70	(720,079)
Beginning Balance (in shares) at Dec. 31, 2018	36,975,203	36,975,203
Beginning Balance at Dec. 31, 2018	$ 145,622	$ 37	830,368	(8)	(684,775)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock relating to employee stock purchase plan (in shares)		74,935
Issuance of common stock relating to employee stock purchase plan	818		818
Stock-based compensation expense	17,922		17,922
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)		687,189
Issuance of common stock in connection with At-The-Market offering, net of issuance costs	10,605	$ 1	10,604
Issuance of common stock in connection with the follow on offering, net of issuance costs (in shares)		13,264,705
Issuance of common stock in connection with the follow on offering, net of issuance costs	$ 211,200	$ 13	211,187
Issuance of common stock upon exercise of stock options and warrants (in shares)	10,135	10,135
Issuance of common stock upon exercise of stock options and warrants	$ 119		119
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)		1,447,544
Issuance of restricted stock awards and performance stock awards, net of cancellation	0	$ 1	(1)
Net settlement of restricted stock awards for employee taxes (in shares)		(84,976)
Net settlement of restricted stock awards for employee taxes	(1,378)		(1,378)
Unrealized gain (loss) and adjustment on securities included in net loss	11			11
Net loss	$ (159,429)				(159,429)
Ending Balance (in shares) at Dec. 31, 2019	52,374,735	52,374,735
Ending Balance at Dec. 31, 2019	$ 225,490	$ 52	1,069,639	3	(844,204)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense			6,544
Capped call transactions			(28,865)
Issuance of common stock in connection with the Teoxane Agreement (in shares)		2,500,000
Issuance of common stock in connection with the Teoxane Agreement		$ 3	43,397
Equity component of convertible senior notes, net of transaction costs of $3,583			108,510
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)		975,000
Issuance of common stock in connection with At-The-Market offering, net of issuance costs		$ 1	15,536
Issuance of common stock upon exercise of stock options and warrants (in shares)		52,352
Issuance of common stock upon exercise of stock options and warrants			572
Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)		1,197,054
Issuance of restricted stock awards and performance stock awards, net of cancellation		$ 1	(1)
Net settlement of restricted stock awards for employee taxes (in shares)		(72,987)
Net settlement of restricted stock awards for employee taxes			(1,401)
Unrealized gain (loss) and adjustment on securities included in net loss	521			521
Net loss	$ (61,933)				(61,933)
Ending Balance (in shares) at Mar. 31, 2020	57,026,154	57,026,154
Ending Balance at Mar. 31, 2020	$ 308,375	$ 57	$ 1,213,931	$ 524	$ (906,137)

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2017
Payments of stock issuance costs	$ 337	$ 201
Equity component of convertible debt, transaction cost	3,583
Follow on Public Offering
Payments of stock issuance costs	$ 44	$ 521
At the Market Offering
Payments of stock issuance costs			$ 265	$ 603
Follow on Public Offering
Payments of stock issuance costs			$ 770	$ 535

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (61,933)	$ (35,304)	$ (159,429)	$ (142,568)	$ (120,587)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			2,909	1,726	1,468
Amortization of premium (discount) on investments	(513)	(649)	(2,637)	(1,103)	410
Stock-based compensation expense	6,544	4,159	17,922	16,273	13,230
Gain on disposal of property and equipment			(8)	(1,466)	0
Impairment of property and equipment			0	0	2,927
Other non-cash operating activities			810	175	767
Non-cash in-process research and development	11,184	0
Amortization of debt discount and issuance costs	1,505	0
Depreciation and amortization	739	628
Other non-cash operating activities	371	88
Changes in operating assets and liabilities:
Accounts receivable	0	27,000	27,000	(26,952)	80
Prepaid expenses and other current assets	(467)	(1,018)	(1,377)	(2,911)	4,849
Operating lease right of use assets	570	(3,440)	(1,868)	0	0
Other non-current assets	175	101	1,578	(1,871)	(403)
Accounts payable			(360)	1,691	2,607
Accruals and other liabilities	(2,373)	(2,298)	3,565	1,488	(690)
Deferred revenue	942	(278)	4,587	51,272	0
Operating lease liabilities	(822)	3,333	1,147	0	0
Accounts payable	789	(3,736)
Net cash used in operating activities	(43,289)	(11,414)	(106,161)	(104,246)	(95,342)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investments	(159,412)	(127,357)	(331,362)	(314,911)	(36,028)
Purchases of property and equipment	(539)	(1,084)	(3,238)	(6,991)	(2,525)
Purchase of intangible assets	(118)	0
Proceeds from maturities of investments	54,500	25,000	317,000	146,000	157,445
Proceeds from sale of property and equipment			8	1,541	0
Proceeds from sale of investments			0	67,435	0
Payment for acquisition of in-process research and development			0	(100)	(100)
CASH FLOWS FROM FINANCING ACTIVITIES	(105,569)	(103,441)	(17,592)	(107,026)	118,792
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of convertible senior notes	287,500	0
Proceeds from issuance of common stock in connection with offerings, net of commissions and discount	15,581	108,100	211,970	0	157,468
Proceeds from issuance of common stock in connection with at-the-market offerings, net of commissions			10,870	0	38,760
Proceeds from the exercise of stock options and common stock warrants, and purchases under the employee stock purchase plan	572	18	937	5,292	4,569
Payment of capped call transactions	(28,865)	0
Payment of convertible senior notes transaction costs	(8,703)	0
Net settlement of restricted stock awards for employee taxes	(1,401)	(1,049)	(1,378)	(2,212)	(573)
Payment of offering costs	(337)	(201)
Payment of offering costs			(742)	(366)	(644)
Principal payments made on financing obligations			0	(932)	(3,636)
Net cash provided by financing activities	264,347	106,868	221,657	1,782	195,944
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			97,904	(209,490)	219,394
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	115,489	(7,987)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period	171,890	73,986	73,986	283,476	64,082
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period	287,379	65,999	171,890	73,986	283,476
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes			3,000	0	0
Cash paid for interest			0	16	299
Issuance of common stock in connection with the Teoxane Agreement	43,400	0
Accrued transaction costs on convertible senior notes	487	0	293	354	251
Property and equipment purchases included in accounts payable and accruals and other current liabilities	247	1,108	$ 619	$ 642	$ 718
Accrued offering costs	$ 0	$ 320

The Company and Summary of Sign

The Company and Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Summary of Significant Accounting Policies	1. The Company and Summary of Significant Accounting Policies The Company Revance Therapeutics, Inc is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines. In November 2019, we submitted the Biologics License Application (“BLA”) to the United States (the “U.S.”) Food and Drug Administration (the “FDA”) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on February 5, 2020, and the Prescription Drug User Fee Act (“PDUFA”) target action date is November 25, 2020. We are also evaluating DaxibotulinumtoxinA for Injection in upper facial lines - glabellar lines, forehead lines and crow’s feet combined — as well as in three therapeutic indications — cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DaxibotulinumtoxinA for Injection, we have begun development of a biosimilar to BOTOX ® ® ® Since inception, we have devoted substantially all of our efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the biosimilar to BOTOX ® ® For three months ended March 31, 2020, we had a net loss of $61.9 million. As of March 31, 2020, we had a working capital surplus of $476.8 million and an accumulated deficit of $906.1 million. In recent years, we have funded our operations primarily through a combination of issuance and sale of common stock and issuance of convertible senior notes. As of March 31, 2020, we had capital resources of $511.3 million consisting of cash, cash equivalents, and short-term investments. We believe that our existing capital resources will fund the operating plan through at least the next 12 months, and may identify additional capital resources to fund our operations. Basis of Presentation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheets for the year ended December 31, 2019 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2020, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements set forth under the heading “ Revance Therapeutics, Inc. Consolidated Financial Statements Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in one segment. Principles of Consolidation Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 COVID-19 Intangible Assets Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use 350-40) 2018-15 internal-use internal-use 350-40 2018-15 2018-15 Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.	1. The Company Revance Therapeutics is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DAXI in glabellar (frown) lines. In November 2019, we submitted the Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (the “FDA”) for DAXI in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on February 5, 2020, and the Prescription Drug User Fee Act (“PDUFA”) target action date is November 25, 2020. If the BLA is approved on or by the target action date, we plan to initiate commercialization activities for DAXI for the treatment of glabellar lines before the end of 2020. We are also evaluating DAXI in upper facial lines - glabellar lines, forehead lines and crow’s feet combined - as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, we have begun development of a biosimilar to BOTOX ® ® Since inception, we have devoted substantially all of our efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DAXI, DaxibotulinumtoxinA Topical, and the biosimilar to BOTOX ® For the year ended December 31, 2019, we had a net loss of $159.4 million. As of December 31, 2019, we had a working capital surplus of $255.6 million and an accumulated deficit of $844.2 million. In recent years, we have funded our operations primarily through the issuance and sale of common stock. As of December 31, 2019, we had capital resources of $290.1 million consisting of cash, cash equivalents, and investments. We believe that our existing capital resources will fund the operating plan through at least the next 12 months following the issuance of this Form 10-K,

Revenue

Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue	2. Revenue Mylan Collaboration and License Agreement Agreement Terms We entered into a collaboration agreement with Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) in February 2018 (the “Mylan Collaboration”), pursuant to which we agreed to collaborate with Mylan exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX ® one-time Under the Mylan Collaboration and as of March 31, 2020, Mylan had paid us an aggregate of $30 million in non-refundable Revenue Recognition In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Mylan Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Mylan. Other than the upfront payment, all other milestones and consideration we may earn under the Mylan Collaboration are subject to uncertainties related to development achievements, Mylan’s rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Mylan Collaboration. We re-evaluate We recognize revenue and estimate deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. For revenue recognition purposes, the development period is estimated to extend through 2024. It is possible that this period will change and is assessed at each reporting date. For the three months ended March 31, 2020 and 2019, we recognized revenue related to development services of $0.1 million and $0.3 million, respectively. As of March 31, 2020 and December 31, 2019, we estimated short-term deferred revenue of $10.1 million and $7.9 million, respectively; and long-term deferred revenue of $15.7 million and $18.0 million, respectively. Fosun License Agreement Agreement Terms In December 2018, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we have granted Fosun the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights. Under the Fosun License Agreement, in January 2019 we received a non-refundable upfront Revenue Recognition We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate No revenue has been recognized from the Fosun License Agreement for the three months ended March 31, 2020 and 2019. Substantially all payments received to date were included in long-term deferred revenue as of March 31, 2020 and December 31, 2019.	3. Revenue Mylan Collaboration and License Agreement Agreement Terms We entered into a collaboration agreement with Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) in February 2018 (the “Mylan Collaboration”), pursuant to which we will collaborate with Mylan exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX ® Pursuant to the Mylan Collaboration, we formed a joint steering committee with Mylan, consisting of an equal number of members from both parties, to oversee and manage the development, manufacturing and commercialization of the biosimilar. We were responsible for conducting initial non-clinical ® (a) non-clinical “ex-U.S. Under the Mylan Collaboration, Mylan paid us a non-refundable The term of the collaboration will continue, on a country-by-country region-by-region Revenue Recognition As of the Mylan Amendment date in August 2019, we have the following unfulfilled non-distinct know-how We considered that the license has standalone functionality and is capable of being distinct. However, we determined that the license is not distinct from the development and manufacturing services within the context of the agreement because the development and manufacturing services significantly increase the utility of the intellectual property. Our development, manufacturing and commercialization license can only provide benefit to Mylan in combination with our development services during initial development and subsequent studies. The intellectual property related to the biosimilar platform, which is proprietary to us, is the foundation for the development activities related to the treatment for all indications. The manufacturing services are a necessary and integral part of the development services as they could only be conducted utilizing the outcomes of these services. Given the development services under the Mylan Collaboration are expected to involve significant further development of the initial intellectual property, we have concluded that the development and compound supply services are not distinct from the license, and thus the license, development services and compound supply services are combined into a single performance obligation. The nature of the combined performance obligation is to provide development and manufacturing services to Mylan under the arrangement. We determined that the Continuation Decision represents a material right, because it includes consideration for the intellectual property license, and provides economic value for the duration of the entire development period, defined as the initial development through regulatory approval. Further, in accordance with ASC 606, we elected to use a practical alternative to estimate the standalone fair value selling price of the material right, which is based on the cost of expected services to be provided for the duration of the contract. In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Mylan Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Mylan. Other than the upfront payment, all other milestones and consideration we may earn under the Mylan Collaboration are subject to uncertainties related to development achievements, Mylan’s rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because as the underlying value relates to the license, the license is the predominant feature in the Mylan Collaboration. The initial estimated transaction price of $81.0 million included the $25.0 million upfront payment, $40.0 million of development milestones, and estimated variable consideration for cost-sharing payments from Mylan. We re-evaluate We recognize revenue and estimate deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. As a result of the extended period of time for Mylan to make the Continuation Decision provided in the Mylan Amendment, both short-term and long-term deferred revenue have been adjusted accordingly to reflect the impact of the extension. For revenue recognition purposes, the development period is estimated to extend through 2024. However, it is possible that this period will change and is assessed at each reporting date. For the year ended December 31, 2019 and 2018, we recognized revenue related to development services of $0.4 million and $3.7 million, respectively. As of December 31, 2019 and 2018, we estimated short-term deferred revenue of $7.9 million and $8.6 million, respectively; and long-term deferred revenue of $18.0 million and $12.7 million, respectively. Fosun License Agreement Agreement Terms In December 2018, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby Revance has granted Fosun the exclusive rights to develop and commercialize our proprietary DAXI in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights. Under the Fosun License Agreement, we are eligible to receive a non-refundable upfront Under the Fosun License Agreement, Fosun will have the right to import, develop, commercialize, market and sell the product in the Fosun Territory or engage service providers for such activities, and we will be responsible for manufacturing the product and supplying it to Fosun for the clinical and commercial activities in the Fosun Territory, subject to the terms of a supply agreement and a quality assurance agreement, each to be entered into between the parties in the six months following the date of the Fosun License Agreement. Except as provided in the Fosun License Agreement, each party has retained all of its intellectual property rights. During the term of the Fosun License Agreement and an additional two years from the termination date if Fosun terminates the Fosun License Agreement, Fosun will not engage in any research, development, manufacture or commercialization of any product competitive with the product; provided that such non-compete and pre-clinical studies The term of the Fosun License Agreement will continue until Fosun’s payment obligations have been performed or have expired, unless sooner terminated by either party pursuant to the terms of the Fosun License Agreement. Either party may terminate the Fosun License Agreement for material breach by, or bankruptcy of, the other party. In addition, we may terminate the Fosun License Agreement if Fosun challenges our patents, and Fosun may terminate the Fosun License Agreement upon 120 days’ notice. In the event of a change of control of us, our successor will have the option to terminate the Agreement by paying Fosun a variable payment that depends on the stage of development of the product. Revenue Recognition We identified the following material promises within the Fosun License Agreement: (1) license to certain intellectual property and know-how know-how know-how, In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered, and concluded only a certain milestone of $1.0 million was included in the transaction price. We will re-evaluate We will recognize revenue on the single performance obligation as control of the manufactured product is supplied to Fosun. As of December 31, 2019, no revenue has been recognized as no supply has been provided under the agreement. Upon commencement of the transfer of control, revenue will be recognized in a pattern consistent with estimated deliveries of the product through the term of the arrangement, which is estimated to extend through 2039. However, it is possible that this period will change and is assessed at each reporting date. The estimated contract term for revenue recognition purposes is not limited or impacted by Fosun’s ability to terminate the agreement to due to a substantive significant termination penalty from non-refundable No revenue has been recognized from the Fosun License Agreement for the year ended December 31, 2019. Substantially all of the $30 million non-refundable

Cash Equivalents and Short-Term

Cash Equivalents and Short-Term Investments	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Cash Equivalents and Short-Term Investments	3. Cash Equivalents and Short-Term Investments Our cash equivalents and short-term investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: March 31, 2020 December 31, 2019 Cost Unrealized Gains Fair Value Unrealized in thousands Cost Gains Losses Fair Value Money market funds $ 179,031 $ — $ 179,031 $ 136,258 $ — $ — $ 136,258 U.S. treasury securities 30,124 182 30,306 48,349 6 — 48,355 U.S. government agency obligations 159,634 342 159,976 5,993 2 (5 ) 5,990 Commercial paper 140,320 — 140,320 77,082 — — 77,082 Overnight repurchase agreements — — — 15,001 — — 15,001 Total cash equivalents and available-for-sale $ 509,109 $ 524 $ 509,633 $ 282,683 $ 8 $ (5 ) $ 282,686 Classified as: Cash equivalents $ 285,012 $ 163,731 Short-term investments 224,621 118,955 Total cash equivalents and available-for-sale $ 509,633 $ 282,686 As of March 31, 2020 and December 31, 2019, we have no other-than-temporary impairments on our available-for-sale available-for-sale one-year.	5. Cash Equivalents and Short-Term Investments Our cash equivalents and short-term investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale The following table is a summary of amortized cost, unrealized gains and losses, and fair value: December 31, 2019 December 31, 2018 Cost Unrealized Fair Value Cost Unrealized Fair Value (in thousands) Gains Losses Gains Losses Money market funds $ 136,258 $ — $ — $ 136,258 $ 38,354 $ — $ — $ 38,354 U.S. treasury securities 48,349 6 — 48,355 80,844 5 (5 ) 80,844 U.S. government agency obligations 5,993 2 (5 ) 5,990 52,586 — (8 ) 52,578 Commercial paper 77,082 — — 77,082 — — — — Overnight repurchase agreements 15,001 — — 15,001 — — — — Total cash equivalents and available-for-sale $ 282,683 $ 8 $ (5 ) $ 282,686 $ 171,784 $ 5 $ (13 ) $ 171,776 Classified as: Cash equivalents $ 163,731 $ 69,220 Short-term investments 118,955 102,556 Total cash equivalents and available-for-sale $ 282,686 $ 171,776 As of December 31, 2019 and 2018, we have no other-than-temporary impairments on our available-for-sale available-for-sale one-year.

Filler Distribution Agreement

Filler Distribution Agreement	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Filler Distribution Agreement	4. Filler Distribution Agreement In January 2020, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid ® ® ® ® ® ® ® ® ® ® two-year If Teoxane pursues regulatory approval for RHA ® The Teoxane Agreement is accounted for as an asset acquisition for the distribution rights of various approved and unapproved products and indications. The aggregate purchase consideration for the distribution rights is $43.5 million, consisting of the fair value of the 2,500,000 shares transferred to Teoxane and transaction costs. The purchase consideration is allocated to the underlying groups of approved and unapproved products based on their relative fair values, of which $11.2 million is allocated to certain unapproved products and future innovations, or in-process ® The following table summarized the distribution rights: March 31, 2020 (in thousands) Initial Carrying Accumulated Net Carrying Distribution rights to approved products and indications $ 32,334 $ — $ 32,334

Derivative Liability

Derivative Liability	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Derivative Liability	5. Derivative Liability In 2012, we entered into a settlement agreement in which we are obligated to pay $4.0 million upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. As of March 31, 2020, the fair value of the derivative liability was $3.0 million, which was measured using a term of 0.7 years based on an expected BLA approval in 2020, a risk-free rate of 0.2% and a credit risk adjustment of 7.5%. As of December 31, 2019, the fair value of the derivative liability was $3.0 million, which was measured using a term of 0.9 years based on an expected BLA approval in 2020, a risk-free rate of 1.6% and a credit risk adjustment of 7.5%.	4. Derivative Liability Due to an existing settlement agreement which we entered in 2012, we are obligated to pay $4.0 million upon our achievement of regulatory approval for DAXI or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. As of December 31, 2018, the fair value of the derivative liability was $2.7 million, which was measured using a term of 1.5 years based on an expected BLA approval in 2020, a risk-free rate of 2.6% and a credit risk adjustment of 8.0%. As of December 31, 2019, the fair value of the derivative liability was $3.0 million, which was measured using a term of 0.9 years based on an expected BLA approval in 2020, a risk-free rate of 1.6% and a credit risk adjustment of 7.5%. As a result of the fair value remeasurements during the years ended December 31, 2019, 2018, and 2017, we recognized aggregate losses of $0.2 million, $0.1 million, and $0.6 million, respectively.

Leases

Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Leases	6. Leases We have non-cancelable The operating lease costs are summarized as follows: Three Months Ended (in thousands) 2020 2019 Operating lease cost $ 1,425 $ 1,343 Variable lease cost (1) 77 290 Total operating lease costs $ 1,502 $ 1,633 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred. As of March 31, 2020, maturities of the Company’s operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2020 remaining nine months $ 5,057 2021 6,942 2022 5,464 2023 5,557 2024 5,733 2025 and thereafter 12,226 Total operating lease payments 40,979 Less imputed interest (1) (12,462 ) Present value of operating lease payments $ 28,517 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. Supplemental cash flow information related to the operating leases was as follows: Three Months Ended (in thousands) 2020 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,677 $ 1,450 Right-of-use $ — $ 3,890	8. Leases We have non-cancelable The operating lease costs are summarized as follows: (in thousands) Year Ended Operating lease cost $ 5,618 Variable lease cost (1) 1,184 Total operating lease costs $ 6,802 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred. As of December 31, 2019, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2020 $ 6,735 2021 6,942 2022 5,464 2023 5,557 2024 5,733 2025 and thereafter 12,226 Total operating lease payments 42,657 Less imputed interest (1) (13,317 ) Present value of operating lease payments $ 29,340 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. As of December 31, 2018, the aggregate total future minimum lease payments under non-cancelable Year Ending December 31, (in thousands) 2019 $ 5,826 2020 6,011 2021 6,196 2022 4,696 2023 and thereafter 20,173 Total payments $ 42,902 Supplemental cash flow information related to the operating leases was as follows: (in thousands) Year Ended Cash paid for amounts included in the measurement of operating lease liabilities $ 6,339 Right-of-use $ 3,890

Convertible Senior Notes

Convertible Senior Notes	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Senior Notes	7. Convertible Senior Notes On February 14, 2020, we issued convertible senior notes that are due in 2027 (the “2027 Notes”) with an aggregate principal balance of $287.5 million, pursuant to an indenture, dated February 14, 2020, between Revance and U.S. Bank National Association, as trustee (the “Indenture”). The 2027 Notes are senior unsecured obligations and bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2020. The 2027 Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received $278.3 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the 2027 Notes were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the RHA ® The 2027 Notes may be converted at any time by the holders prior to the close of business on the business day immediately preceding November 15, 2026 only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on June 30, 2020 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per $1,000 principal amount of the 2027 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the 2027 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after November 15, 2026 until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their 2027 Notes at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election. The conversion rate will initially be 30.8804 shares of our common stock per $1,000 principal amount of the 2027 Notes (equivalent to an initial conversion price of approximately $32.38 per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its 2027 Notes in connection with such a corporate event or notice of redemption, as the case may be. We may not redeem the 2027 Notes prior to February 20, 2024. We may redeem for cash all or any portion of the 2027 Notes, at our option, on or after February 20, 2024 if the last reported sale price of our common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to 100% of the principal amount of the 2027 Notes to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2027 Notes. If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. In accounting for the issuance of the 2027 Notes, we separated the 2027 Notes into liability and equity components. The carrying amount of the liability component was $175.4 million, which was calculated by using a discount rate of 9.5%, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was $112.1 million, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the 2027 Notes. The equity component of the 2027 Notes is included in additional paid-in Total transaction costs for the issuance of the 2027 Notes were $9.2 million, consisting of initial purchasers’ discount, commissions, and other issuance costs. We allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were $5.6 million, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the 2027 Notes. The transaction costs attributed to the equity component were $3.6 million, which were included in additional paid-in Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: (in thousands) Three Months Ended Contractual interest expense $ 643 Amortization of debt discount (1) 1,461 Amortization of debt issuance costs (2) 44 Total interest expense $ 2,148 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the three months ended March 31, 2020, which remained unchanged from the issuance date. As of March 31, 2020, the unamortized debt discount was $110.6 million, and will be amortized over 6.9 years. (2) As of March 31, 2020, the unamortized debt issuance cost for the 2027 Notes was $5.6 million on the condensed consolidated balance sheets. As of March 31, 2020, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs, which are summarized as follows: (in thousands) March 31, 2020 2027 Notes $ 287,500 Less: Unamortized debt discount and debt issuance costs (116,195 ) Carrying amount of 2027 Notes $ 171,305 Capped Call Transactions Concurrently with the 2027 Notes, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used $28.9 million of the net proceeds from the 2027 Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the 2027 Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted 2027 Notes, as the case may be, with such reduction and/or offset subject to a price cap of $48.88 of our common stock per share, which represents a premium of 100% over the last reported sale price of our common stock on February 10, 2020. The capped calls have an initial strike price of $32.38 per share, subject to certain adjustments, which corresponds to the conversion option strike price in the 2027 Notes. The capped call transactions cover, subject to anti-dilution adjustments, approximately 8.9 million shares of our common stock. The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the 2027 Notes. As the capped call transactions meet certain accounting criteria, the premium paid of $28.9 million was recorded as a reduction in additional paid-in

Stockholders' Equity and Stock-

Stockholders' Equity and Stock-Based Compensation	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation	8. Stockholders’ Equity and Stock-Based Compensation Common Stock Warrants As of December 31, 2019, warrants to purchase 34,113 shares of common stock were outstanding at an exercise price of $14.95 per share, which expired in May 2020. In February 2020, warrants to purchase 34,113 shares of common stock were net exercised for 11,134 shares of common stock. As of March 31, 2020, no common stock warrants were outstanding. 2014 Equity Incentive Plan (the “2014 EIP”) On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 EIP increased by 2,094,989 shares. For the three months ended March 31, 2020, 765,675 stock options and 1,261,225 restricted stock awards, including 215,000 performance stock awards, were granted under the 2014 EIP. As of March 31, 2020, 929,364 shares were available for issuance under the 2014 EIP. 2014 Inducement Plan (the “2014 IN”) For the three months ended March 31, 2020, no stock options or restricted stock awards were granted under the 2014 IN. As of March 31, 2020, 246,130 shares were available for issuance under the 2014 IN. 2014 Employee Stock Purchase Plan (the “2014 ESPP”) On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by 300,000 shares. As of March 31, 2020, 1,704,005 shares were available for issuance under the 2014 ESPP. Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, underlying shares of convertible senior notes, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards and performance stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: March 31, 2020 2019 Convertible senior notes 8,878,938 — Outstanding common stock options 5,305,185 4,372,676 Unvested restricted stock awards and performance stock awards 2,799,982 768,770 Shares of common stock expected to be purchased on June 30 under the 2014 ESPP 49,861 35,619 Outstanding common stock warrants — 34,113 Follow-On In December 2019, we completed a follow-on At-The-Market We are party to a controlled equity offering sales agreement with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “2018 ATM Agreement”), under which we may offer and sell common stock having aggregate proceeds of up to $125.0 million through Cantor Fitzgerald as our sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon our instructions, and we will pay a commission to Cantor Fitzgerald of up to 3.0% of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the three months ended March 31, 2020, no common stock was sold under the 2018 ATM Agreement. Stock-based Compensation Stock-based compensation expense was allocated as follows: Three Months Ended (in thousands) 2020 2019 Research and development $ 2,442 $ 2,079 Selling, general and administrative 4,102 2,080 Total stock-based compensation $ 6,544 $ 4,159	11. Stockholders’ Equity Common Stock Warrants As of both December 31, 2019 and December 31, 2018, 34,113, common stock warrants were outstanding at an exercise price of $14.95 per share, which expire in 2020. Follow-On In December 2017, we completed a follow-on follow-on In January 2019, we completed a follow-on follow-on In December 2019, we completed a follow-on follow-on follow-on At-The-Market In March 2016, we entered into the 2016 At-The-Market In March 2018, we terminated the 2016 ATM Agreement and entered into a separate ATM agreement with Cantor Fitzgerald (the “2018 ATM Agreement”). Under the 2018 ATM Agreement, we may offer and sell common stock having aggregate proceeds of up to $125.0 million from time to time through Cantor Fitzgerald as our sales agent. Sales of common stock through Cantor Fitzgerald under the 2018 ATM Agreement will be made by means of ordinary brokers’ transactions on the Nasdaq or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cantor Fitzgerald. Cantor Fitzgerald will sell the common stock from time to time, based upon instructions from us. We agreed to pay Cantor Fitzgerald a commission of up to 3.0% of the gross sales proceeds of any common stock sold through Cantor Fitzgerald under the 2018 ATM Agreement. For the year ended December 31, 2019, we sold 687,189 shares of common stock under the 2018 ATM Agreement at a weighted average price of $15.82 per share resulting in net proceeds of $10.9 million after underwriting discounts, commissions and other offering expenses.

Fair Value Measurements

Fair Value Measurements	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	9. Fair Value Measurements The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: March 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 179,031 $ 179,031 $ — $ — U.S. treasury securities 30,306 30,306 — — U.S. government agency obligations 159,976 — 159,976 — Commercial paper 140,320 — 140,320 — Total assets measured at fair value $ 509,633 $ 209,337 $ 300,296 $ — Liabilities Derivative liability $ 3,042 $ — $ — $ 3,042 Total liabilities measured at fair value $ 3,042 $ — $ — $ 3,042 December 31, 2019 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 136,258 $ 136,258 $ — $ — U.S. treasury securities 48,355 48,355 — — Commercial paper 77,082 — 77,082 — Overnight repurchase agreements 15,001 — 15,001 — U.S. government agency obligations 5,990 — 5,990 — Total assets measured at fair value $ 282,686 $ 184,613 $ 98,073 $ — Liabilities Derivative liability $ 2,952 $ — $ — $ 2,952 Total liabilities measured at fair value $ 2,952 $ — $ — $ 2,952 For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trade of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Fair value as of December 31, 2019 $ 2,952 Change in fair value 90 Fair value as of March 31, 2020 $ 3,042 The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (Note 5). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment. The fair value of the 2027 Notes (Note 7) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We carry 2027 Notes at face value less unamortized debt discount and issuance costs on our condensed consolidated balance sheets and present the fair value for disclosure purposes only. As of March 31, 2020, the fair value of the 2027 Notes was $229.5 million.	6. Fair Value Measurement The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: As of December 31, 2019 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 136,258 $ 136,258 $ — $ — U.S. treasury securities 48,355 48,355 — — Commercial paper 77,082 — 77,082 — Overnight repurchase agreements 15,001 — 15,001 — U.S. government agency obligations 5,990 — 5,990 — Total assets measured at fair value $ 282,686 $ 184,613 $ 98,073 $ — Liabilities Derivative liability $ 2,952 $ — $ — $ 2,952 Total liabilities measured at fair value $ 2,952 $ — $ — $ 2,952 As of December 31, 2018 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 38,354 $ 38,354 $ — $ — U.S. treasury securities 80,844 80,844 — — U.S. government agency obligations 52,578 — 52,578 — Total assets measured at fair value $ 171,776 $ 119,198 $ 52,578 $ — Liabilities Derivative liability $ 2,753 $ — $ — $ 2,753 Total liabilities measured at fair value $ 2,753 $ — $ — $ 2,753 For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Fair value as of December 31, 2018 $ 2,753 Change in fair value 199 Fair value as of December 31, 2019 $ 2,952 The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment ( Note 4

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Teoxane Agreement We are parties to the Teoxane Agreement (Note 4), which will be effective for a term of ten years upon product launch and may be extended for a two-year Other Purchase Commitments We are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma Other Contingencies We are obligated to pay $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of March 31, 2020, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. We entered into an asset purchase agreement (the “BTRX Purchase Agreement”) with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of March 31, 2020, a one-time We entered into an agreement with BioSentinel, Inc. (“BioSentinel”), under which we in-license one-time Indemnification We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. For the three months ended March 31, 2020, no amounts associated with the indemnification agreements have been recorded.	9. Commitments and Contingencies Purchase Commitments We are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma non-refundable Contingencies We are obligated to pay a $2.0 million milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of December 31, 2019, the milestone has not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products. We entered into an asset purchase agreement (the “BTRX Purchase Agreement”) with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to $16.0 million to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of December 31, 2019, a one-time We entered into an agreement with BioSentinel, Inc. (“BioSentinel”), under which we in-license one-time Indemnification We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future, but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. For the year ended December 31, 2019, no amounts associated with the indemnification agreements have been recorded.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation Our consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, Revance Therapeutics Limited and Revance International Limited, and have been prepared in conformity with United States (“U.S.”) generally accepted accounting principles (“GAAP”). We operate in one segment. All intercompany transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, impairment of long-lived assets and the valuation of deferred tax assets. We base our estimates on historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates. Risks and Uncertainties The product candidates developed by us require approvals from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that our current and future product candidates will meet desired efficacy and safety requirements to obtain the necessary approvals. If approval is denied or delayed, it may have a material adverse impact on our business and our consolidated financial statements. We are subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of our product candidates, ability to obtain regulatory approval of our product candidates, the need for substantial additional financing to achieve our goals, uncertainty of broad adoption of our approved products, if any, by physicians and consumers, significant competition and untested manufacturing capabilities. Concentration of Credit Risk Financial instruments that potentially subject us to a concentration of credit risk consist of short-term investments. Under our investment policy, we limit our credit exposure by investing in highly liquid funds and debt obligations of the United States (U.S.) government and its agencies with high credit quality. Our cash, cash equivalents, and short-term investments are held in the U.S. Such deposits may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash, cash equivalents, and short-term investments. Cash and Cash Equivalents We consider all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include deposit, money market funds, and debt securities. Restricted Cash As of December 31, 2019 and 2018, a deposit totaling $0.7 million was restricted from withdrawal. We have a deposit balance of $0.5 million that relates to securing our facility lease and will remain until the end of the lease. The remaining $0.2 million deposit balance relates to a letter of credit. These balances are included in restricted cash on the accompanying consolidated balance sheets and within the cash, cash equivalents, and restricted cash balance on the consolidated statement of cash flows. Investments Investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. We determine the appropriate classification of our investments at the time of purchase and reevaluate such determination at each balance sheet date. All of our investments are classified as available-for-sale Fair Value of Financial Instruments We use fair value measurements to record fair value adjustments to certain financial and non-financial The three levels of inputs that may be used to measure fair value are as follows: • Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances. Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and software, lab equipment and furniture and fixtures, and manufacturing equipment is depreciated generally over 3, 5, and 7 years, respectively. Leasehold improvements are depreciated over the lesser of 15 years or the term of the lease. The cost of maintenance and repairs is expensed as incurred. When property and equipment are retired or otherwise disposed of, the costs and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized. Impairment of Long-lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. Events and changes in circumstances considered important that could result in an impairment review of long-lived assets include (i) a significant decrease in the market price of a long-lived asset; (ii) a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, including an adverse action or assessment by a regulator; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; and (vi) a current expectation that, more likely than not (more than 50%), a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The impairment evaluation of long-lived assets includes an analysis of estimated future undiscounted net cash flows expected to be generated by the long-lived assets over their remaining estimated useful lives. If the estimate of future undiscounted net cash flows is insufficient to recover the carrying value of the long-lived assets over the remaining estimated useful lives, we record an impairment loss in the amount by which the carrying value of the long-lived assets exceeds the fair value. Fair value is generally measured based on discounted cash flow analysis. Clinical Trial Accruals and Prepaid Expenses Clinical trial costs are charged to research and development expense as incurred. We accrue for expenses resulting from contracts with clinical research organizations (CROs), consultants, and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid expense, which will be expensed as services are rendered. The CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs and other miscellaneous costs. We determine accrual estimates through reports from and discussion with clinical personnel and outside services providers as to the progress or state of completion of trials, or the services completed. We estimate accrued expenses as of each balance sheet date based on the facts and circumstances known to us at that time. Our clinical trial accrual is dependent, in part, upon the receipt of timely and accurate reporting from the CROs and other third-party vendors. Revenue Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers Note 3 To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Licenses of intellectual property If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front non-refundable, up-front Milestone payments At the inception of each arrangement that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered more likely than not of being reached and estimate the amount to be included in the transaction price. ASC 606 provides two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used should be consistently applied throughout the life of the contract; however, it is not necessary for us to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of us or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation (as determined to be appropriate) on a relative stand-alone selling price basis. We recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate catch-up Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Up-front Research and Development Expense Research and development expense are charged to operations as incurred. Research and development expense include, but are not limited to, personnel expenses, clinical trial supplies, fees for clinical trial services, manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation, and utilities. Assets acquired that are utilized in research and development that have no alternative future use are also expensed as incurred. Income Taxes We account for income taxes under the asset and liability method. We estimate actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in our consolidated statements of operations and comprehensive loss become deductible expenses under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of our deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized. We must assess the likelihood that our deferred tax assets will be recovered from future taxable income, and to the extent we believe that recovery is not likely, we establish a valuation allowance. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2019 and 2018. We intend to maintain valuation allowances until sufficient evidence exists to support our reversal. Stock-Based Compensation We have an equity compensation plan under which various types of stock-based awards including, but not limited to, stock option, restricted stock awards, and performance stock awards, may be granted to employees, non-employee non-employee We measure our stock-based awards using the estimated grant-date fair values. For stock options issued under the 2014 Equity Incentive Plan (“2014 EIP”) and the 2014 Inducement Plan (“2014 IN”), and shares purchased under the 2014 Employee Stock Purchase Plan (the “2014 ESPP”), fair values are determined using the Black-Scholes option pricing model. For restricted stock awards including performance stock awards subject to performance-based vesting conditions, the grant-date fair values are the closing prices of our common stocks on the grant dates. For performance stock awards subject to market-based vesting conditions, fair values are determined using the Monte Carlo simulation model. For stock-based awards other than performance stock awards subject to performance-based vesting conditions, the value of the stock-based awards is recognized as compensation expense over the requisite service period (generally the vesting period). For performance stock awards subject to performance-based vesting conditions, the value of the stock-based awards is recognized as compensation expense when the performance condition is probable of achievement. Stock-based compensation expenses are classified in the consolidated statements of operations and comprehensive loss based on the functional area to which the related recipients belong. Forfeitures are recognized when they occur. Effective July 1, 2018, we adopted ASU 2018-07, Compensation—Stock Compensation (Topic 718) non-employee non-employee non-employee 2018-07. Derivative Liability We bifurcated and separately accounted for derivative instruments related to payment provisions underlying a derivative liability. This derivative is accounted for as a liability, which will be remeasured to fair value as of each balance sheet date, with changes in fair value recognized in the consolidated statements of operations and comprehensive loss. We will continue to record adjustments to the fair value of the derivative liability associated with derivative liability until the remaining settlement payment has been paid. Contingencies From time to time, we may have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. We expect that contingencies related to regulatory approval milestones will only become probable once such regulatory outcome is achieved. We are not subject to any known current pending legal matters or claims that would have a material adverse effect on our financial position, results of operations or cash flows. Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards including unvested performance stock awards are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: As of December 31, 2019 2018 2017 Outstanding common stock options 4,734,616 3,605,333 3,210,400 Outstanding common stock warrants 34,113 34,113 34,113 Unvested restricted stock awards 1,808,518 605,012 639,287 Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) right-of-use 2018-10, Leases (Topic 842), Codification Improvements 2018-11, Leases (Topic 842), Targeted Improvements 2018-10 2018-11 provides 2018-11 ASU 2019-01, 2019-01 Transition disclosures related to Topic 250, Accounting Changes and Error Corrections 2019-01 2018-11, 2018-10, 2016-02, 2019-01 2018-11 right-of-use right-of-use non-lease non-lease non-lease right-of-use Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use 350-40) 2018-15 internal-use internal-use 350-40 2018-15 2018-15 In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. 2019-12 2019-12 removes 2019-12 2019-12

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2019
Balance Sheet Components [Abstract]
Balance Sheet Components	7. Balance Sheet Components Property and Equipment, net Property and equipment, net consists of the following: As of December 31, (in thousands) 2019 2018 Manufacturing equipment $ 19,113 $ 11,307 Leasehold improvements 5,374 4,752 Construction in progress 2,386 8,925 Computer software 2,040 1,299 Computer equipment 1,505 1,351 Furniture and fixtures 1,203 787 Total property and equipment 31,621 28,421 Less: Accumulated depreciation (16,866 ) (13,972 ) Property and equipment, net $ 14,755 $ 14,449 Accruals and Other Current Liabilities Accruals and other current liabilities consist of the following: As of December 31, (in thousands) 2019 2018 Accruals related to: Compensation $ 7,933 $ 6,743 Clinical trials 4,746 4,021 Professional service 2,732 2,272 Nonrecurring milestone payment 1,000 1,000 Manufacturing and quality control 1,798 260 Property and equipment (including construction in progress) 221 111 Other current liabilities 206 541 Total accruals and other current liabilities $ 18,636 $ 14,948 (1) We recorded $5.5 million and $5.3 million for bonus accruals as of December 31, 2019 and 2018, respectively.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	10. Stock-Based Compensation Equity Compensation Plans We maintain three equity compensation plans: 2014 Equity Incentive Plan (the “2014 EIP”), 2014 Inducement Plan (the “2014 IN”) and 2014 Employee Stock Purchase Plan (the “2014 ESPP”). Under the 2014 EIP and 2014 IN, stock options may be granted with different vesting terms with maximum contractual term of 10 years from the grant dates. Under the 2014 EIP and the 2014 IN, stock options typically vest over four years, either with 25% of the total grant vesting on the first anniversary of the grant date and 1/36 th th 2014 EIP The 2014 EIP was effective on February 5, 2014, and the plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other forms of equity compensation to qualified employees, directors and consultants. The common stock shares reserved for issuance under the 2014 EIP will automatically increase each year on January 1 st st 2014 IN The 2014 IN was effective on August 29, 2014, and the plan provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and other forms of equity compensation exclusively to individuals that were not previously employees or directors of us, as an inducement material to the individual’s entry into employment with us Stockholder approval of the 2014 IN was not required pursuant to Rule 5635 (c)(4) of the Nasdaq Listing Rules. For the year ended December 31, 2019, no stock options or restricted stock awards were granted under the 2014 IN. As of December 31, 2019, 174,546 common stock shares were available for issuance under the 2014 IN. 2014 ESPP The 2014 ESPP was effective on February 5, 2014, and the plan provides employees with an opportunity to purchase our common stock through accumulated payroll deductions. The common stock shares reserved for issuance under the 2014 ESPP will automatically increase each year on January 1 st st Stock Options The following table summarizes our stock option activities: Shares Weighted Weighted Weighted- Aggregate (1) (in thousands) Balance as of December 31, 2016 2,790,646 $ 19.31 Granted 960,525 $ 21.75 $ 13.59 Exercised (309,341 ) $ 12.88 $ 7,073 Forfeited (231,430 ) $ 22.76 Balance as of December 31, 2017 3,210,400 $ 20.41 Granted 1,136,650 $ 28.30 $ 16.35 Exercised (293,100 ) $ 15.45 $ 1,519 Forfeited (448,617 ) $ 25.59 Balance as of December 31, 2018 3,605,333 $ 22.66 Granted 1,976,750 $ 14.53 $ 8.29 Exercised (10,135 ) $ 11.76 $ 45 Forfeited (837,332 ) $ 22.40 Balance as of December 31, 2019 4,734,616 $ 19.34 6.2 $ 7,762 Exercisable as of December 31, 2019 2,659,741 $ 21.31 3.9 $ 3,433 (1) The total intrinsic values of options exercised as of December 31, 2019, 2018 and 2017 were determined by multiplying the number of shares by the difference between exercise price of the stock options and the fair value of the common stock as of December 31, 2019, 2018 and 2017 of $16.23, $20.13 and $35.75 per share, respectively. The intrinsic values of outstanding and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock as of December 31, 2019. Restricted Stock Awards The following table summarizes our activities of restricted stock awards, including performance stock awards: Shares Weighted- Unvested balance as of December 31, 2016 416,229 $ 20.02 Granted 435,525 $ 22.08 Vested (130,562 ) $ 23.25 Forfeited (81,905 ) $ 19.32 Unvested balance as of December 31, 2017 639,287 $ 20.86 Granted 373,500 $ 28.37 Vested (235,307 ) $ 20.25 Forfeited (172,468 ) $ 24.83 Unvested balance as of December 31, 2018 605,012 $ 24.61 Granted 1,640,275 $ 12.78 Vested (244,038 ) $ 23.80 Forfeited (192,731 ) $ 21.47 Unvested balance as of December 31, 2019 1,808,518 $ 14.32 For the year ended December 31, 2019, we granted 865,000 shares of performance stock awards with weighted-average grant-date fair value of $10.78 per share. The performance stock awards will vest based on certain market and performance conditions, and all 865,000 shares were unvested as of December 31, 2019. There were no performance stock awards granted prior to 2019. Stock-based Awards Valuation Stock Option and 2014 ESPP Shares The fair value of both stock options and the option component of shares purchased under our 2014 ESPP was estimated using the Black-Scholes option pricing model. The description of the significant assumptions used in the model are as follows: • Fair Value of Common Stock • Expected Term at-the-money; non-transferable non-hedgeable, non-employees 2018-07 Note 2 • Expected Volatility • Risk-Free Interest Rate • Expected Dividend Rate • Forfeitures. The fair values of stock options were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions in 2019: Year Ended Expected term (in years) 6.03 Expected volatility 60.2 % Risk-free interest rate 2.1 % Expected dividend rate — % The fair values of the option component of the shares purchased under the 2014 ESPP were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions for years presented: Year Ended December 31, 2019 2018 2017 Expected term (in years) 0.5 0.5 0.5 Expected volatility 43.4 % 50.9 % 59.2 % Risk-free interest rate 2.3 % 1.9 % 0.9 % Expected dividend rate — % — % — % Stock Option Assumptions Before 2019 Effective July 1, 2018, we adopted ASU 2018-07 Note 2 non-employee non-employee non-employees, Year Ended December 31, 2018 2017 Expected term (in years) 5.5 8.9 Expected volatility 59.4 % 67.9 % Risk-free interest rate 2.8 % 2.3 % Expected dividend rate — % — % ASU 2018-07 non-employee non-employee Year Ended December 31, 2018 2017 Expected term (in years) 6.0 6.0 Expected volatility 60.2 % 67.7 % Risk-free interest rate 2.7 % 2.1 % Expected dividend rate — % — % Performance Stock Awards Subject to Market-based Vesting Conditions Certain performance stock awards granted in 2019 include market-based vesting conditions (“market-based PSAs”). These market-based PSAs vest upon the earlier of i) the date that the closing share price of our common stock meet certain minimum share prices on a volume-weighted basis for a specified period of time or ii) upon a change in control in which the purchase price of our common stock is at or above the same minimum share prices as determined in the award agreement. We determined the fair value of the market-based PSAs using the Monte Carlo simulation model. The following weighted-average assumptions were used in the Monte Carlo simulation model in determining fair value of these performance stock awards: Year Ended Expected term (in years) (1) 10.0 Expected volatility (2) 60.0 % Risk-free interest rate 1.8 % Expected dividend rate — % (1) Expected term was based on the expiration period of the performance stock awards in the award agreement. (2) Expected volatility was based on the historical volatilities of a group of similar entities combined with our historical volatility. For the year ended December 31, 2019, we recognized stock-based compensation expense of $0.5 million for the market-based PSAs. Stock-based compensation expense was allocated as follows: (in thousands) Year Ended December 31, 2019 2018 2017 Research and development $ 8,512 $ 7,480 $ 5,902 General and administrative 9,410 8,793 7,328 Total stock-based compensation expense $ 17,922 $ 16,273 $ 13,230 Unrecognized Compensation Cost As of December 31, 2019 2018 Unrecognized Weighted Unrecognized Weighted (in thousands) (in years) (in thousands) (in years) Stock options $ 18,487 2.9 $ 20,202 2.7 Restricted stock awards 11,891 2.3 10,591 2.4 Performance stock awards 8,839 2.4 — — Total unrecognized compensation cost $ 39,217 2.6 $ 30,793 2.6

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes From inception through December 31, 2019, we have only generated pretax losses. Loss before income taxes were as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Domestic $ (159,429 ) $ (139,568 ) $ (118,331 ) Foreign — — (2,256 ) Loss before income taxes $ (159,429 ) $ (139,568 ) $ (120,587 ) Statutory Federal Income Tax Provision (Benefit) Reconciliations of the statutory federal income tax provision (benefit) to our effective tax are as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Tax benefit at statutory federal rate (1) $ (33,480 ) $ (29,309 ) $ (40,999 ) Research and development credits (4,723 ) (4,064 ) (1,858 ) Other changes in valuation allowance 36,379 42,902 (35,783 ) Nondeductible/nontaxable items 1,429 108 738 Other 395 (153 ) 224 Sale of intellectual property (2) — (14,008 ) 14,008 Foreign rate differential and withholding taxes — 2,370 767 Impact of the Tax Reform Act — 5,154 62,903 Income tax provision $ — $ 3,000 $ — (1) U.S. federal statutory rate was 21%, for the years ended December 31, 2019 and 2018, and 35% for the year ended December 31, 2017. (2) This represents the tax effect of an intra-entity sale between us and our wholly owned subsidiary, Revance International Limited, which was eliminated for financial reporting purposes (discussed below). Deferred Tax Assets, Net Components of our deferred tax assets, net were as follows: Year Ended December 31, (in thousands) 2019 2018 Deferred tax assets Net operating loss carryforward $ 184,879 $ 146,618 Accruals and reserves 1,537 2,191 Stock-based compensation 6,241 5,173 Tax credits 17,449 12,230 Fixed and intangible assets 2,803 3,328 Deferred revenue 10,703 — Operating lease liabilities 6,174 — Other 19 — Total deferred tax assets 229,805 169,540 Less: valuation allowance (1) (224,222 ) (169,540 ) Deferred tax assets, gross 5,583 — Deferred tax liabilities Operating lease right of use assets (5,583 ) — Deferred tax assets, net $ — $ — (1) The valuation allowance for the year ended December 31, 2019 increased by $54.7 million, compared to the same period in 2018, primarily due to net operating losses and credits generated in those years. Valuation Allowance We have evaluated the positive and negative evidence bearing upon our ability to realize the deferred tax assets. We have considered our history of cumulative net losses incurred since inception and have concluded that it is more likely than not that we will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the deferred tax assets due to the uncertainty of realizing future tax benefits from our net operating loss (“NOL”) carryforwards and other deferred tax assets as of December 31, 2019 and 2018. We reevaluate the positive and negative evidence at each reporting period. Net Operation Loss and Tax Credits Carryforwards As of December 31, 2019, we had NOL carryforwards available to reduce future taxable income, if any, for federal, California, and other states income tax purposes of $734.6 million, $398.2 million, and $281.7 million, respectively. The California NOL carryforwards will begin to expire in 2028. If not utilized, the federal and the other states NOL carryforwards will begin expiring in 2020 and 2030, respectively. As of December 31, 2019, we had research and development credit carryforwards of $9.1 million and $7.6 million available to reduce future taxable income, if any, for federal and California income tax purposes, respectively. The federal research and development credit carryforwards will begin expiring in 2023 if they are not utilized, and the California research and development credit carryforwards have no expiration date. As of December 31, 2019, we had orphan drug credit carryforwards of $7.7 million available to reduce future taxable income, if any, for federal income tax purposes. The federal orphan drug credit carryforwards will begin expiring in 2038 if they are not utilized. In general, if we experience a greater than 50% aggregate change in ownership over a 3-year pre-change tax-exempt California State Apportionment In 2018, we petitioned the California Franchise Tax Board for an alternative apportionment percentage due to the insignificant apportionment percentage derived from the single sales factor methodology for California. In January 2019, the California Franchise Tax Board approved the use of an alternative apportionment method. Our NOL in California is estimated to increase by approximately $219 million as a result of the change in apportionment model. We have increased our deferred tax assets by $15 million with a corresponding offsetting adjustment to its valuation allowance. There is no impact to the our net loss in the period as a result of the adjustment. Tax Cuts and Jobs Act In December 2017, the U.S. government enacted Tax Cuts and Jobs Act (the “Tax Reform Act”). The Tax Reform Act includes but not limited to, reducing the U.S. federal corporate tax rate from 35% to 21%, allowing for federal NOL to be carried over indefinitely for NOL generated after December 31, 2017 with statutory limitations to the annual utilization, and creating a new limitation on deductible interest expense. We have completed our assessment of the accounting impact resulting from the Tax Reform Act in December 2018, and the aggregated impact to deferred taxes is $68.1 million, which continues to be fully offset by a valuation allowance. In October 2017, we created a wholly owned subsidiary, Revance International Limited, which was incorporated in the Cayman Islands, and transferred the economic rights to certain intellectual property for $41.2 million to the newly formed subsidiary. Under the tax laws prior to the Tax Reform Act in December 2017, the transaction had no financial statement impact to us other than to decrease the current NOL by the amount of the consideration. As a result of the Tax Reform Act, we did not complete the accounting with regard to the tax effects associated with this intra-entity transfer as of December 31, 2017. In October 2018, we received notification that the Internal Revenue Service (IRS) had approved our request to disregard the Cayman subsidiary by treating it as a U.S. branch for federal income tax purposes, effectively eliminating any tax effects from the transaction. As a result of the finalization of our assessment of the Tax Reform Act, we have reversed the usage of the NOLs from this transaction as of December 31, 2018. Unrecognized Tax Benefits We follow the provisions of the FASB’s guidance for accounting for uncertain tax positions. The guidance indicates a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded in the financial statements due to the fact the liabilities have been netted against deferred attribute carryovers. It is our policy to include penalties and interest related to income tax matters in income tax expense. We do not expect that our uncertain tax positions will materially change in the next twelve months. For year ending December 31, 2019, the amount of unrecognized tax benefits increased due to additional research and development credits generated. The additional uncertain tax benefits would not impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. The unrecognized tax benefit was as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Balance at the beginning of the period $ 4,200 $ 2,577 $ 1,819 Additions for prior years — 333 — Additions for current year 1,498 1,290 758 Balance at the end of the period $ 5,698 $ 4,200 $ 2,577 We file income tax returns in the U.S., California, and other states. We are not currently under examination by income tax authorities in any federal, state or other jurisdictions. All tax returns will remain open for examination by the federal and state authorities for three and four years, respectively, from the date of utilization of any NOL or tax credits.

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events With the inclusion of these interim financial statements in this Registration statement on Form S-4 10-Q one-time	13. Subsequent Events Stock Options and Restricted Stock Awards Grants under the 2014 EIP In January 2020, we granted 568,675 stock options and 1,027,825 restricted stock awards including performance stock awards under the 2014 EIP to existing employees. Teoxane Exclusive Distribution Agreement In January 2020, we entered into the Teoxane Agreement with Teoxane, pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid ® ® ® ® ® ® ® ® ® two-year We have begun to build out a U.S. commercial organization and plan to introduce the FDA approved RHA ® If Teoxane pursues regulatory approval for RHA ® We are currently assessing the accounting impact of the Teoxane Agreement. Convertible Senior Notes Due 2027 On February 14, 2020, we issued an aggregate of $287.5 million principal amount of notes, pursuant to an Indenture (Exhibit 4.2) between Revance and U.S. Bank National Association, as trustee (the “Notes”). The Notes are senior unsecured obligations of Revance and will bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2020. The Notes will mature on February 15, 2027, unless earlier converted, redeemed or repurchased. The Notes are convertible into cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. We received approximately $278.4 million in net proceeds, after deducting the initial purchasers’ discount, commissions, and estimated expenses payable by us, from the issuance of the Notes. We may not redeem the Notes prior to February 20, 2024, and no sinking fund is provided for the Notes. We used approximately $28.9 million of the net proceeds from the Notes to pay the cost of certain capped call transactions. The capped call transactions are expected generally to reduce potential dilution to our common stock upon any conversion of Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes. We are currently assessing the accounting impact of the Notes and the capped call transactions.

Quarterly Results of Operations

Quarterly Results of Operations	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Quarterly Results of Operations (Unaudited)	14. Quarterly Results of Operations (Unaudited) The following table presents our unaudited consolidated quarterly financial data. This information has been prepared on a basis consistent with that of the audited consolidated financial statements. We believe that all necessary adjustments, consisting of normal recurring accruals and adjustments, have been included to present fairly the quarterly financial data. The results of historical periods are not necessarily indicative of the results of operations for any future period. Three Months Ended 2019 2018 December 31, September 30, June 30, March 31, December 31, September 30, June 30, March 31, (in thousands, except per share amounts) Revenue $ 89 $ 46 $ — $ 278 $ 487 $ 2,362 $ 686 $ 193 Loss from operations $ (46,170 ) $ (42,540 ) $ (39,122 ) $ (36,627 ) $ (38,412 ) $ (33,641 ) $ (34,919 ) $ (35,662 ) Net loss $ (45,326 ) $ (41,409 ) $ (37,390 ) $ (35,304 ) $ (40,616 ) $ (32,834 ) $ (34,080 ) $ (35,037 ) Basic and diluted net loss $ (45,326 ) $ (41,409 ) $ (37,390 ) $ (35,304 ) $ (40,616 ) $ (32,834 ) $ (34,080 ) $ (35,037 ) Basic and diluted net loss per share (1) $ (0.99 ) $ (0.96 ) $ (0.86 ) $ (0.85 ) $ (1.12 ) $ (0.91 ) $ (0.94 ) $ (0.97 ) (1) Net loss per share amounts are calculated discretely and therefore may not add up to the total due to rounding.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. Our condensed consolidated balance sheets for the year ended December 31, 2019 was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending December 31, 2020, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements set forth under the heading “ Revance Therapeutics, Inc. Consolidated Financial Statements Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in one segment.	Our consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, Revance Therapeutics Limited and Revance International Limited, and have been prepared in conformity with United States (“U.S.”) generally accepted accounting principles (“GAAP”).
Principles of Consolidation	Principles of Consolidation Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.	All intercompany transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 COVID-19	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such management estimates include revenue recognition, deferred revenue, accruals including clinical trial accruals, stock-based compensation, fair value of derivative liability, impairment of long-lived assets and the valuation of deferred tax assets. We base our estimates on historical experience and also on assumptions that we believe are reasonable; however, actual results could significantly differ from those estimates.
Risks and Uncertainties		Risks and Uncertainties The product candidates developed by us require approvals from the U.S. Food and Drug Administration (“FDA”) or foreign regulatory agencies prior to commercial sales. There can be no assurance that our current and future product candidates will meet desired efficacy and safety requirements to obtain the necessary approvals. If approval is denied or delayed, it may have a material adverse impact on our business and our consolidated financial statements. We are subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of our product candidates, ability to obtain regulatory approval of our product candidates, the need for substantial additional financing to achieve our goals, uncertainty of broad adoption of our approved products, if any, by physicians and consumers, significant competition and untested manufacturing capabilities.
Concentration of Credit Risk		Concentration of Credit Risk Financial instruments that potentially subject us to a concentration of credit risk consist of short-term investments. Under our investment policy, we limit our credit exposure by investing in highly liquid funds and debt obligations of the United States (U.S.) government and its agencies with high credit quality. Our cash, cash equivalents, and short-term investments are held in the U.S. Such deposits may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash, cash equivalents, and short-term investments.
Cash and Cash Equivalents		Cash and Cash Equivalents We consider all highly liquid investment securities with remaining maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents may include deposit, money market funds, and debt securities.
Restricted Cash		Restricted Cash As of December 31, 2019 and 2018, a deposit totaling $0.7 million was restricted from withdrawal. We have a deposit balance of $0.5 million that relates to securing our facility lease and will remain until the end of the lease. The remaining $0.2 million deposit balance relates to a letter of credit. These balances are included in restricted cash on the accompanying consolidated balance sheets and within the cash, cash equivalents, and restricted cash balance on the consolidated statement of cash flows.
Investments		Investments Investments generally consist of securities with original maturities greater than three months and remaining maturities of less than one year, while long-term investments generally consist of securities with remaining maturities greater than one year. We determine the appropriate classification of our investments at the time of purchase and reevaluate such determination at each balance sheet date. All of our investments are classified as available-for-sale
Fair Value of Financial Instruments		Fair Value of Financial Instruments We use fair value measurements to record fair value adjustments to certain financial and non-financial The three levels of inputs that may be used to measure fair value are as follows: • Level 1 — Observable inputs, such as quoted prices in active markets for identical assets or liabilities; • Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and • Level 3 — Valuations based on unobservable inputs to the valuation methodology and including data about assumptions market participants would use in pricing the asset or liability based on the best information available under the circumstances.
Property and Equipment, Net		Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment and software, lab equipment and furniture and fixtures, and manufacturing equipment is depreciated generally over 3, 5, and 7 years, respectively. Leasehold improvements are depreciated over the lesser of 15 years or the term of the lease. The cost of maintenance and repairs is expensed as incurred. When property and equipment are retired or otherwise disposed of, the costs and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.
Impairment of Long-Lived Assets		Impairment of Long-lived Assets We evaluate long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. Events and changes in circumstances considered important that could result in an impairment review of long-lived assets include (i) a significant decrease in the market price of a long-lived asset; (ii) a significant adverse change in the extent or manner in which a long-lived asset is being used or in its physical condition; (iii) a significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, including an adverse action or assessment by a regulator; (iv) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of a long-lived asset; (v) a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of a long-lived asset; and (vi) a current expectation that, more likely than not (more than 50%), a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The impairment evaluation of long-lived assets includes an analysis of estimated future undiscounted net cash flows expected to be generated by the long-lived assets over their remaining estimated useful lives. If the estimate of future undiscounted net cash flows is insufficient to recover the carrying value of the long-lived assets over the remaining estimated useful lives, we record an impairment loss in the amount by which the carrying value of the long-lived assets exceeds the fair value. Fair value is generally measured based on discounted cash flow analysis.
Clinical Trial Accruals		Clinical Trial Accruals and Prepaid Expenses Clinical trial costs are charged to research and development expense as incurred. We accrue for expenses resulting from contracts with clinical research organizations (CROs), consultants, and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate expense in the consolidated financial statements by matching the appropriate expenses with the period in which services and efforts are expended. In the event advance payments are made to a CRO, the payments will be recorded as a prepaid expense, which will be expensed as services are rendered. The CRO contracts generally include pass-through fees including, but not limited to, regulatory expenses, investigator fees, travel costs and other miscellaneous costs. We determine accrual estimates through reports from and discussion with clinical personnel and outside services providers as to the progress or state of completion of trials, or the services completed. We estimate accrued expenses as of each balance sheet date based on the facts and circumstances known to us at that time. Our clinical trial accrual is dependent, in part, upon the receipt of timely and accurate reporting from the CROs and other third-party vendors.
Revenue		Revenue Effective January 1, 2018, we adopted Accounting Standards Codification Topic 606, Revenue from Contracts with Customers Note 3 To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within the contract and determine those that are performance obligations and assess whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Licenses of intellectual property If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from non-refundable, up-front non-refundable, up-front Milestone payments At the inception of each arrangement that includes development, regulatory or commercial milestone payments, we evaluate whether the milestones are considered more likely than not of being reached and estimate the amount to be included in the transaction price. ASC 606 provides two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. Whichever method is used should be consistently applied throughout the life of the contract; however, it is not necessary for us to use the same approach for all contracts. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of us or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation (as determined to be appropriate) on a relative stand-alone selling price basis. We recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate catch-up Royalties For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Up-front
Research and Development Expenditures		Research and Development Expense Research and development expense are charged to operations as incurred. Research and development expense include, but are not limited to, personnel expenses, clinical trial supplies, fees for clinical trial services, manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation, and utilities. Assets acquired that are utilized in research and development that have no alternative future use are also expensed as incurred.
Income Taxes		Income Taxes We account for income taxes under the asset and liability method. We estimate actual current tax exposure together with assessing temporary differences resulting from differences in accounting for reporting purposes and tax purposes for certain items, such as accruals and allowances not currently deductible for tax purposes. These temporary differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. In general, deferred tax assets represent future tax benefits to be received when certain expenses previously recognized in our consolidated statements of operations and comprehensive loss become deductible expenses under applicable income tax laws or when net operating loss or credit carryforwards are utilized. Accordingly, realization of our deferred tax assets is dependent on future taxable income against which these deductions, losses and credits can be utilized. We must assess the likelihood that our deferred tax assets will be recovered from future taxable income, and to the extent we believe that recovery is not likely, we establish a valuation allowance. Based on the available evidence, we are unable, at this time, to support the determination that it is more likely than not that our deferred tax assets will be utilized in the future. Accordingly, we recorded a full valuation allowance as of December 31, 2019 and 2018. We intend to maintain valuation allowances until sufficient evidence exists to support our reversal.
Stock-Based Compensation		Stock-Based Compensation We have an equity compensation plan under which various types of stock-based awards including, but not limited to, stock option, restricted stock awards, and performance stock awards, may be granted to employees, non-employee non-employee We measure our stock-based awards using the estimated grant-date fair values. For stock options issued under the 2014 Equity Incentive Plan (“2014 EIP”) and the 2014 Inducement Plan (“2014 IN”), and shares purchased under the 2014 Employee Stock Purchase Plan (the “2014 ESPP”), fair values are determined using the Black-Scholes option pricing model. For restricted stock awards including performance stock awards subject to performance-based vesting conditions, the grant-date fair values are the closing prices of our common stocks on the grant dates. For performance stock awards subject to market-based vesting conditions, fair values are determined using the Monte Carlo simulation model. For stock-based awards other than performance stock awards subject to performance-based vesting conditions, the value of the stock-based awards is recognized as compensation expense over the requisite service period (generally the vesting period). For performance stock awards subject to performance-based vesting conditions, the value of the stock-based awards is recognized as compensation expense when the performance condition is probable of achievement. Stock-based compensation expenses are classified in the consolidated statements of operations and comprehensive loss based on the functional area to which the related recipients belong. Forfeitures are recognized when they occur. Effective July 1, 2018, we adopted ASU 2018-07, Compensation—Stock Compensation (Topic 718) non-employee non-employee non-employee 2018-07.
Derivative Liabilities		Derivative Liability We bifurcated and separately accounted for derivative instruments related to payment provisions underlying a derivative liability. This derivative is accounted for as a liability, which will be remeasured to fair value as of each balance sheet date, with changes in fair value recognized in the consolidated statements of operations and comprehensive loss. We will continue to record adjustments to the fair value of the derivative liability associated with derivative liability until the remaining settlement payment has been paid.
Contingencies		Contingencies From time to time, we may have certain contingent liabilities that arise in the ordinary course of business activities. We accrue a liability for such matters when it is probable that future expenditures will be made and can be reasonably estimated. We expect that contingencies related to regulatory approval milestones will only become probable once such regulatory outcome is achieved. We are not subject to any known current pending legal matters or claims that would have a material adverse effect on our financial position, results of operations or cash flows.
Net Loss per Share Attributable to Common Stockholders		Net Loss per Share Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards including unvested performance stock awards are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive.
Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use 350-40) 2018-15 internal-use internal-use 350-40 2018-15 2018-15 Recent Accounting Pronouncements The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.	Recently Adopted Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) right-of-use 2018-10, Leases (Topic 842), Codification Improvements 2018-11, Leases (Topic 842), Targeted Improvements 2018-10 2018-11 provides 2018-11 ASU 2019-01, 2019-01 Transition disclosures related to Topic 250, Accounting Changes and Error Corrections 2019-01 2018-11, 2018-10, 2016-02, 2019-01 2018-11 right-of-use right-of-use non-lease non-lease non-lease right-of-use Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other—Internal-Use 350-40) 2018-15 internal-use internal-use 350-40 2018-15 2018-15 In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. 2019-12 2019-12 removes 2019-12 2019-12
Intangible Assets	Intangible Assets Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development

Cash Equivalents and Short-Te_2

Cash Equivalents and Short-Term Investments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]
Available-for-sale Securities	The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: March 31, 2020 December 31, 2019 Cost Unrealized Gains Fair Value Unrealized in thousands Cost Gains Losses Fair Value Money market funds $ 179,031 $ — $ 179,031 $ 136,258 $ — $ — $ 136,258 U.S. treasury securities 30,124 182 30,306 48,349 6 — 48,355 U.S. government agency obligations 159,634 342 159,976 5,993 2 (5 ) 5,990 Commercial paper 140,320 — 140,320 77,082 — — 77,082 Overnight repurchase agreements — — — 15,001 — — 15,001 Total cash equivalents and available-for-sale $ 509,109 $ 524 $ 509,633 $ 282,683 $ 8 $ (5 ) $ 282,686 Classified as: Cash equivalents $ 285,012 $ 163,731 Short-term investments 224,621 118,955 Total cash equivalents and available-for-sale $ 509,633 $ 282,686	The following table is a summary of amortized cost, unrealized gains and losses, and fair value: December 31, 2019 December 31, 2018 Cost Unrealized Fair Value Cost Unrealized Fair Value (in thousands) Gains Losses Gains Losses Money market funds $ 136,258 $ — $ — $ 136,258 $ 38,354 $ — $ — $ 38,354 U.S. treasury securities 48,349 6 — 48,355 80,844 5 (5 ) 80,844 U.S. government agency obligations 5,993 2 (5 ) 5,990 52,586 — (8 ) 52,578 Commercial paper 77,082 — — 77,082 — — — — Overnight repurchase agreements 15,001 — — 15,001 — — — — Total cash equivalents and available-for-sale $ 282,683 $ 8 $ (5 ) $ 282,686 $ 171,784 $ 5 $ (13 ) $ 171,776 Classified as: Cash equivalents $ 163,731 $ 69,220 Short-term investments 118,955 102,556 Total cash equivalents and available-for-sale $ 282,686 $ 171,776

Filler Distribution Agreement (

Filler Distribution Agreement (Tables)	3 Months Ended
	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table summarized the distribution rights: March 31, 2020 (in thousands) Initial Carrying Accumulated Net Carrying Distribution rights to approved products and indications $ 32,334 $ — $ 32,334

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Convertible Debt	Interest expense relating to the 2027 Notes in the condensed consolidated statements of operations and comprehensive loss are summarized as follows: (in thousands) Three Months Ended Contractual interest expense $ 643 Amortization of debt discount (1) 1,461 Amortization of debt issuance costs (2) 44 Total interest expense $ 2,148 (1) The effective interest rate on the liability component of the 2027 Notes was 9.5% for the three months ended March 31, 2020, which remained unchanged from the issuance date. As of March 31, 2020, the unamortized debt discount was $110.6 million, and will be amortized over 6.9 years. (2) As of March 31, 2020, the unamortized debt issuance cost for the 2027 Notes was $5.6 million on the condensed consolidated balance sheets. As of March 31, 2020, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the 2027 Notes, net of unamortized debt discounts and debt issuance costs, which are summarized as follows: (in thousands) March 31, 2020 2027 Notes $ 287,500 Less: Unamortized debt discount and debt issuance costs (116,195 ) Carrying amount of 2027 Notes $ 171,305

Stockholders' Equity and Stoc_2

Stockholders' Equity and Stock-Based Compensation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Equity [Abstract]
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: March 31, 2020 2019 Convertible senior notes 8,878,938 — Outstanding common stock options 5,305,185 4,372,676 Unvested restricted stock awards and performance stock awards 2,799,982 768,770 Shares of common stock expected to be purchased on June 30 under the 2014 ESPP 49,861 35,619 Outstanding common stock warrants — 34,113	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: As of December 31, 2019 2018 2017 Outstanding common stock options 4,734,616 3,605,333 3,210,400 Outstanding common stock warrants 34,113 34,113 34,113 Unvested restricted stock awards 1,808,518 605,012 639,287
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended (in thousands) 2020 2019 Research and development $ 2,442 $ 2,079 Selling, general and administrative 4,102 2,080 Total stock-based compensation $ 6,544 $ 4,159	Stock-based compensation expense was allocated as follows: (in thousands) Year Ended December 31, 2019 2018 2017 Research and development $ 8,512 $ 7,480 $ 5,902 General and administrative 9,410 8,793 7,328 Total stock-based compensation expense $ 17,922 $ 16,273 $ 13,230

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Instruments	The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: March 31, 2020 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 179,031 $ 179,031 $ — $ — U.S. treasury securities 30,306 30,306 — — U.S. government agency obligations 159,976 — 159,976 — Commercial paper 140,320 — 140,320 — Total assets measured at fair value $ 509,633 $ 209,337 $ 300,296 $ — Liabilities Derivative liability $ 3,042 $ — $ — $ 3,042 Total liabilities measured at fair value $ 3,042 $ — $ — $ 3,042 December 31, 2019 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 136,258 $ 136,258 $ — $ — U.S. treasury securities 48,355 48,355 — — Commercial paper 77,082 — 77,082 — Overnight repurchase agreements 15,001 — 15,001 — U.S. government agency obligations 5,990 — 5,990 — Total assets measured at fair value $ 282,686 $ 184,613 $ 98,073 $ — Liabilities Derivative liability $ 2,952 $ — $ — $ 2,952 Total liabilities measured at fair value $ 2,952 $ — $ — $ 2,952	The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy: As of December 31, 2019 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 136,258 $ 136,258 $ — $ — U.S. treasury securities 48,355 48,355 — — Commercial paper 77,082 — 77,082 — Overnight repurchase agreements 15,001 — 15,001 — U.S. government agency obligations 5,990 — 5,990 — Total assets measured at fair value $ 282,686 $ 184,613 $ 98,073 $ — Liabilities Derivative liability $ 2,952 $ — $ — $ 2,952 Total liabilities measured at fair value $ 2,952 $ — $ — $ 2,952 As of December 31, 2018 (in thousands) Fair Value Level 1 Level 2 Level 3 Assets Money market funds $ 38,354 $ 38,354 $ — $ — U.S. treasury securities 80,844 80,844 — — U.S. government agency obligations 52,578 — 52,578 — Total assets measured at fair value $ 171,776 $ 119,198 $ 52,578 $ — Liabilities Derivative liability $ 2,753 $ — $ — $ 2,753 Total liabilities measured at fair value $ 2,753 $ — $ — $ 2,753
Summary of Changes in Fair Value of Financial Instruments	The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Fair value as of December 31, 2019 $ 2,952 Change in fair value 90 Fair value as of March 31, 2020 $ 3,042	The following table summarizes the change in the fair value of our Level 3 financial instrument: (in thousands) Derivative Fair value as of December 31, 2018 $ 2,753 Change in fair value 199 Fair value as of December 31, 2019 $ 2,952

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: March 31, 2020 2019 Convertible senior notes 8,878,938 — Outstanding common stock options 5,305,185 4,372,676 Unvested restricted stock awards and performance stock awards 2,799,982 768,770 Shares of common stock expected to be purchased on June 30 under the 2014 ESPP 49,861 35,619 Outstanding common stock warrants — 34,113	Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below: As of December 31, 2019 2018 2017 Outstanding common stock options 4,734,616 3,605,333 3,210,400 Outstanding common stock warrants 34,113 34,113 34,113 Unvested restricted stock awards 1,808,518 605,012 639,287

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2019
Balance Sheet Components [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consists of the following: As of December 31, (in thousands) 2019 2018 Manufacturing equipment $ 19,113 $ 11,307 Leasehold improvements 5,374 4,752 Construction in progress 2,386 8,925 Computer software 2,040 1,299 Computer equipment 1,505 1,351 Furniture and fixtures 1,203 787 Total property and equipment 31,621 28,421 Less: Accumulated depreciation (16,866 ) (13,972 ) Property and equipment, net $ 14,755 $ 14,449
Schedule of Accruals and Other Current Liabilities	Accruals and other current liabilities consist of the following: As of December 31, (in thousands) 2019 2018 Accruals related to: Compensation $ 7,933 $ 6,743 Clinical trials 4,746 4,021 Professional service 2,732 2,272 Nonrecurring milestone payment 1,000 1,000 Manufacturing and quality control 1,798 260 Property and equipment (including construction in progress) 221 111 Other current liabilities 206 541 Total accruals and other current liabilities $ 18,636 $ 14,948 (1) We recorded $5.5 million and $5.3 million for bonus accruals as of December 31, 2019 and 2018, respectively.

Leases Leases (Tables)

Leases Leases (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating Lease Costs	The operating lease costs are summarized as follows: Three Months Ended (in thousands) 2020 2019 Operating lease cost $ 1,425 $ 1,343 Variable lease cost (1) 77 290 Total operating lease costs $ 1,502 $ 1,633 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.	The operating lease costs are summarized as follows: (in thousands) Year Ended Operating lease cost $ 5,618 Variable lease cost (1) 1,184 Total operating lease costs $ 6,802 (1) Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.
Operating Lease Liability Maturities	As of March 31, 2020, maturities of the Company’s operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2020 remaining nine months $ 5,057 2021 6,942 2022 5,464 2023 5,557 2024 5,733 2025 and thereafter 12,226 Total operating lease payments 40,979 Less imputed interest (1) (12,462 ) Present value of operating lease payments $ 28,517 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates.	As of December 31, 2019, maturities of our operating lease liabilities are as follows: Year Ending December 31, (in thousands) 2020 $ 6,735 2021 6,942 2022 5,464 2023 5,557 2024 5,733 2025 and thereafter 12,226 Total operating lease payments 42,657 Less imputed interest (1) (13,317 ) Present value of operating lease payments $ 29,340 (1) Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of 12.0%, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates.
Schedule of Future Minimum Rental Payments for Operating Leases under ASC 840		As of December 31, 2018, the aggregate total future minimum lease payments under non-cancelable Year Ending December 31, (in thousands) 2019 $ 5,826 2020 6,011 2021 6,196 2022 4,696 2023 and thereafter 20,173 Total payments $ 42,902
Supplemental Cash Flow Information	Supplemental cash flow information related to the operating leases was as follows: Three Months Ended (in thousands) 2020 2019 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,677 $ 1,450 Right-of-use $ — $ 3,890	Supplemental cash flow information related to the operating leases was as follows: (in thousands) Year Ended Cash paid for amounts included in the measurement of operating lease liabilities $ 6,339 Right-of-use $ 3,890

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Stock Option Activity		The following table summarizes our stock option activities: Shares Weighted Weighted Weighted- Aggregate (1) (in thousands) Balance as of December 31, 2016 2,790,646 $ 19.31 Granted 960,525 $ 21.75 $ 13.59 Exercised (309,341 ) $ 12.88 $ 7,073 Forfeited (231,430 ) $ 22.76 Balance as of December 31, 2017 3,210,400 $ 20.41 Granted 1,136,650 $ 28.30 $ 16.35 Exercised (293,100 ) $ 15.45 $ 1,519 Forfeited (448,617 ) $ 25.59 Balance as of December 31, 2018 3,605,333 $ 22.66 Granted 1,976,750 $ 14.53 $ 8.29 Exercised (10,135 ) $ 11.76 $ 45 Forfeited (837,332 ) $ 22.40 Balance as of December 31, 2019 4,734,616 $ 19.34 6.2 $ 7,762 Exercisable as of December 31, 2019 2,659,741 $ 21.31 3.9 $ 3,433 (1) The total intrinsic values of options exercised as of December 31, 2019, 2018 and 2017 were determined by multiplying the number of shares by the difference between exercise price of the stock options and the fair value of the common stock as of December 31, 2019, 2018 and 2017 of $16.23, $20.13 and $35.75 per share, respectively. The intrinsic values of outstanding and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock as of December 31, 2019.
Nonvested Restricted Stock Shares Activity		The following table summarizes our activities of restricted stock awards, including performance stock awards: Shares Weighted- Unvested balance as of December 31, 2016 416,229 $ 20.02 Granted 435,525 $ 22.08 Vested (130,562 ) $ 23.25 Forfeited (81,905 ) $ 19.32 Unvested balance as of December 31, 2017 639,287 $ 20.86 Granted 373,500 $ 28.37 Vested (235,307 ) $ 20.25 Forfeited (172,468 ) $ 24.83 Unvested balance as of December 31, 2018 605,012 $ 24.61 Granted 1,640,275 $ 12.78 Vested (244,038 ) $ 23.80 Forfeited (192,731 ) $ 21.47 Unvested balance as of December 31, 2019 1,808,518 $ 14.32
Fair Value Assumptions		the fair values of the stock options vested were remeasured at each reporting date using the Black-Scholes option pricing model with the following weighted-average assumptions: Year Ended December 31, 2018 2017 Expected term (in years) 5.5 8.9 Expected volatility 59.4 % 67.9 % Risk-free interest rate 2.8 % 2.3 % Expected dividend rate — % — % The fair values of the employee and non-employee Year Ended December 31, 2018 2017 Expected term (in years) 6.0 6.0 Expected volatility 60.2 % 67.7 % Risk-free interest rate 2.7 % 2.1 % Expected dividend rate — % — %
Schedule of Stock-based Compensation Expense	Stock-based compensation expense was allocated as follows: Three Months Ended (in thousands) 2020 2019 Research and development $ 2,442 $ 2,079 Selling, general and administrative 4,102 2,080 Total stock-based compensation $ 6,544 $ 4,159	Stock-based compensation expense was allocated as follows: (in thousands) Year Ended December 31, 2019 2018 2017 Research and development $ 8,512 $ 7,480 $ 5,902 General and administrative 9,410 8,793 7,328 Total stock-based compensation expense $ 17,922 $ 16,273 $ 13,230
Schedule of Unrecognized Stock-Based Compensation Cost		Unrecognized Compensation Cost As of December 31, 2019 2018 Unrecognized Weighted Unrecognized Weighted (in thousands) (in years) (in thousands) (in years) Stock options $ 18,487 2.9 $ 20,202 2.7 Restricted stock awards 11,891 2.3 10,591 2.4 Performance stock awards 8,839 2.4 — — Total unrecognized compensation cost $ 39,217 2.6 $ 30,793 2.6
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions		The fair values of stock options were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions in 2019: Year Ended Expected term (in years) 6.03 Expected volatility 60.2 % Risk-free interest rate 2.1 % Expected dividend rate — %
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions		The fair values of the option component of the shares purchased under the 2014 ESPP were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions for years presented: Year Ended December 31, 2019 2018 2017 Expected term (in years) 0.5 0.5 0.5 Expected volatility 43.4 % 50.9 % 59.2 % Risk-free interest rate 2.3 % 1.9 % 0.9 % Expected dividend rate — % — % — %
Performance-based Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair Value Assumptions		The following weighted-average assumptions were used in the Monte Carlo simulation model in determining fair value of these performance stock awards: Year Ended Expected term (in years) (1) 10.0 Expected volatility (2) 60.0 % Risk-free interest rate 1.8 % Expected dividend rate — % (1) Expected term was based on the expiration period of the performance stock awards in the award agreement. (2) Expected volatility was based on the historical volatilities of a group of similar entities combined with our historical volatility.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	Loss before income taxes were as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Domestic $ (159,429 ) $ (139,568 ) $ (118,331 ) Foreign — — (2,256 ) Loss before income taxes $ (159,429 ) $ (139,568 ) $ (120,587 )
Reconciliations of Statutory Federal Income Tax to Effective Tax Rate	Reconciliations of the statutory federal income tax provision (benefit) to our effective tax are as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Tax benefit at statutory federal rate (1) $ (33,480 ) $ (29,309 ) $ (40,999 ) Research and development credits (4,723 ) (4,064 ) (1,858 ) Other changes in valuation allowance 36,379 42,902 (35,783 ) Nondeductible/nontaxable items 1,429 108 738 Other 395 (153 ) 224 Sale of intellectual property (2) — (14,008 ) 14,008 Foreign rate differential and withholding taxes — 2,370 767 Impact of the Tax Reform Act — 5,154 62,903 Income tax provision $ — $ 3,000 $ — (1) U.S. federal statutory rate was 21%, for the years ended December 31, 2019 and 2018, and 35% for the year ended December 31, 2017. (2) This represents the tax effect of an intra-entity sale between us and our wholly owned subsidiary, Revance International Limited, which was eliminated for financial reporting purposes (discussed below).
Significant Components of Deferred Tax Assets	Components of our deferred tax assets, net were as follows: Year Ended December 31, (in thousands) 2019 2018 Deferred tax assets Net operating loss carryforward $ 184,879 $ 146,618 Accruals and reserves 1,537 2,191 Stock-based compensation 6,241 5,173 Tax credits 17,449 12,230 Fixed and intangible assets 2,803 3,328 Deferred revenue 10,703 — Operating lease liabilities 6,174 — Other 19 — Total deferred tax assets 229,805 169,540 Less: valuation allowance (1) (224,222 ) (169,540 ) Deferred tax assets, gross 5,583 — Deferred tax liabilities Operating lease right of use assets (5,583 ) — Deferred tax assets, net $ — $ — (1) The valuation allowance for the year ended December 31, 2019 increased by $54.7 million, compared to the same period in 2018, primarily due to net operating losses and credits generated in those years.
Unrecognized Tax Benefit	The unrecognized tax benefit was as follows: Year Ended December 31, (in thousands) 2019 2018 2017 Balance at the beginning of the period $ 4,200 $ 2,577 $ 1,819 Additions for prior years — 333 — Additions for current year 1,498 1,290 758 Balance at the end of the period $ 5,698 $ 4,200 $ 2,577

Quarterly Results of Operatio_2

Quarterly Results of Operations (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Information	The following table presents our unaudited consolidated quarterly financial data. This information has been prepared on a basis consistent with that of the audited consolidated financial statements. We believe that all necessary adjustments, consisting of normal recurring accruals and adjustments, have been included to present fairly the quarterly financial data. The results of historical periods are not necessarily indicative of the results of operations for any future period. Three Months Ended 2019 2018 December 31, September 30, June 30, March 31, December 31, September 30, June 30, March 31, (in thousands, except per share amounts) Revenue $ 89 $ 46 $ — $ 278 $ 487 $ 2,362 $ 686 $ 193 Loss from operations $ (46,170 ) $ (42,540 ) $ (39,122 ) $ (36,627 ) $ (38,412 ) $ (33,641 ) $ (34,919 ) $ (35,662 ) Net loss $ (45,326 ) $ (41,409 ) $ (37,390 ) $ (35,304 ) $ (40,616 ) $ (32,834 ) $ (34,080 ) $ (35,037 ) Basic and diluted net loss $ (45,326 ) $ (41,409 ) $ (37,390 ) $ (35,304 ) $ (40,616 ) $ (32,834 ) $ (34,080 ) $ (35,037 ) Basic and diluted net loss per share (1) $ (0.99 ) $ (0.96 ) $ (0.86 ) $ (0.85 ) $ (1.12 ) $ (0.91 ) $ (0.94 ) $ (0.97 ) (1) Net loss per share amounts are calculated discretely and therefore may not add up to the total due to rounding.

The Company and Summary of Si_2

The Company and Summary of Significant Accounting Policies- Additional Information (Detail) $ in Thousands	3 Months Ended									12 Months Ended
	Mar. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Dec. 31, 2019USD ($)segment	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Operating Segments | segment	1									1
Net loss	$ 61,933	$ 45,326	$ 41,409	$ 37,390	$ 35,304	$ 40,616	$ 32,834	$ 34,080	$ 35,037	$ 159,429	$ 142,568	$ 120,587
Working capital surplus	476,800	255,600								255,600
Accumulated deficit	906,137	844,204				$ 684,775				844,204	$ 684,775
Cash, cash equivalents, and short-term investments	$ 511,300	$ 290,100								$ 290,100
Cash and cash equivalents, and investments, expected funding term for operating plan (in months)	12 months									12 months

Cash Equivalents and Short-Te_3

Cash Equivalents and Short-Term Investments (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Cost	$ 509,109,000	$ 282,683,000	$ 171,784,000
Gross unrealized gain	524,000	8,000	5,000
Gross unrealized loss		(5,000)	(13,000)
Fair Value	509,633,000	282,686,000	171,776,000
Other-than-temporary impairments on available-for-sale securities	0	0	0
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	285,012,000	163,731,000	69,220,000
Short-term investments
Debt Securities, Available-for-sale [Line Items]
Fair Value	224,621,000	118,955,000
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	179,031,000	136,258,000	38,354,000
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	179,031,000	136,258,000	38,354,000
U.S. treasury securities
Debt Securities, Available-for-sale [Line Items]
Cost	30,124,000	48,349,000	80,844,000
Gross unrealized gain	182,000	6,000	5,000
Gross unrealized loss		0	(5,000)
Fair Value	30,306,000	48,355,000	80,844,000
U.S. government agency obligations
Debt Securities, Available-for-sale [Line Items]
Cost	159,634,000	5,993,000	52,586,000
Gross unrealized gain	342,000	2,000	0
Gross unrealized loss		(5,000)	(8,000)
Fair Value	159,976,000	5,990,000	52,578,000
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Cost	140,320,000	77,082,000	0
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	140,320,000	77,082,000	0
Overnight repurchase agreements
Debt Securities, Available-for-sale [Line Items]
Cost	0	15,001,000	0
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	$ 0	$ 15,001,000	$ 0

Filler Distribution Agreement -

Filler Distribution Agreement - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2020	Mar. 31, 2020	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Non-cash in-process research and development		$ 11,184	$ 0
Teoxane Agreement
Finite-Lived Intangible Assets [Line Items]
Stock issued during period, purchase of assets (in shares)	2,500,000
Collaborative agreement, contractual period	10 years	10 years
Collaborative agreement, extended contractual period	2 years	2 years
Fair value of assets acquired	$ 43,500

Filler Distribution Agreement_2

Filler Distribution Agreement - Distributions Rights (Details) - Distribution Rights $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life	4 years
Initial Carrying Amount	$ 32,334
Accumulated Amortization	0
Net Carrying Amount	$ 32,334

Leases Leases (Details)

Leases Leases (Details)	Mar. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted average remaining lease term	6 years 9 months 18 days	7 years
Extended term of lease	14 years	14 years

Leases Leases - Operating Lease

Leases Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 1,425	$ 1,343	$ 5,618
Variable lease cost	77	290	1,184
Total operating lease costs	$ 1,502	$ 1,633	$ 6,802

Leases Leases - Operating Lea_2

Leases Leases - Operating Lease Liability Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Jan. 01, 2019
Leases [Abstract]
2020 remaining nine months	$ 5,057
2020		$ 6,735
2021	6,942	6,942
2022	5,464	5,464
2023	5,557	5,557
2024	5,733	5,733
2025 and thereafter	12,226	12,226
Total operating lease payments	40,979	42,657
Less imputed interest	(12,462)	(13,317)
Present value of operating lease payments	$ 28,517	$ 29,340	$ 28,200
Weighted average discounted rate (percent)	12.00%	12.00%

Leases Leases - Supplemental Ca

Leases Leases - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 1,677	$ 1,450	$ 6,339
Right-of-use assets obtained in exchange for operating lease liabilities	$ 0	$ 3,890	$ 3,890

Convertible Senior Notes (Detai

Convertible Senior Notes (Details)	Feb. 14, 2020USD ($)day$ / shares	Mar. 31, 2020USD ($)	Mar. 31, 2019USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes		$ 287,500,000	$ 0
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Principal amount of notes	$ 287,500,000
Stated interest rate (percent)	1.75%
Proceeds from issuance of convertible senior notes	$ 278,300,000
Threshold trading days | day	20
Threshold consecutive trading days | day	30
Threshold percentage of stock price trigger	130.00%
Conversion ratio	0.0308804
Conversion price (in dollars per share) | $ / shares	$ 32.38
Redemption price, percentage	100.00%
Long-term debt	$ 175,400,000	$ 171,305,000
Effective percentage		9.50%
Carrying amount of equity component	$ 112,100,000
Debt issuance costs		$ 9,200,000
Debt issuance costs, liability component		5,600,000
Debt issuance costs, equity component		$ 3,600,000
Convertible Debt | 2027 Notes | Debt Conversion Terms One
Debt Instrument [Line Items]
Threshold trading days | day	20
Threshold consecutive trading days | day	30
Threshold percentage of stock price trigger	130.00%
Convertible Debt | 2027 Notes | Debt Conversion Terms Two
Debt Instrument [Line Items]
Threshold trading days | day	5
Threshold consecutive trading days | day	10
Threshold percentage of stock trading price	98.00%

Convertible Senior Notes - Inte

Convertible Senior Notes - Interest Expense (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020USD ($)
Debt Instrument [Line Items]
Contractual interest expense	$ 643
Amortization of debt discount	1,461
Amortization of debt issuance costs	44
Total interest expense	$ 2,148
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Effective percentage	9.50%
Unamortized discount	$ 110,600
Remaining discount amortization period	6 years 10 months 24 days
Debt issuance costs, net	$ 5,600

Convertible Senior Notes - Carr

Convertible Senior Notes - Carrying Amount of Liability Component (Details) - Convertible Debt - 2027 Notes - USD ($) $ in Thousands	Mar. 31, 2020	Feb. 14, 2020
Debt Instrument [Line Items]
2027 Notes	$ 287,500
Less: Unamortized debt discount and debt issuance costs	(116,195)
Carrying amount of 2027 Notes	$ 171,305	$ 175,400

Convertible Senior Notes - Capp

Convertible Senior Notes - Capped Call Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands, shares in Millions	Feb. 14, 2020	Mar. 31, 2020	Mar. 31, 2019
Debt Instrument [Line Items]
Payment of capped call transactions	$ 28,900	$ 28,865	$ 0
Price cap (in dollars per share)	$ 48.88
Premium percentage over sale price	100.00%
Number of shares subject to anti-dilution adjustments (in shares)		8.9
Convertible Debt | 2027 Notes
Debt Instrument [Line Items]
Conversion price (in dollars per share)	$ 32.38

Stockholders' Equity and Stoc_3

Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details) - USD ($)	1 Months Ended							3 Months Ended		12 Months Ended
	Feb. 29, 2020	Jan. 31, 2020	Dec. 31, 2019	Jan. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2016	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 01, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)										1,976,750	1,136,650	960,525
Proceeds from issuance of common stock										$ 10,870,000	$ 0	$ 38,760,000
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			641,813					929,364		641,813			2,094,989
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			174,546					246,130		174,546
Shares underlying stock options granted (in shares)										0
Granted (in shares)										0
Share price (in dollars per share)			$ 16.23			$ 35.75				$ 16.23	$ 20.13	$ 35.75
2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)													300,000
Follow on Public Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)			6,500,000	6,764,705		5,389,515
Share price (in dollars per share)			$ 17	$ 17		$ 31				$ 17		$ 31
Proceeds from issuance of common stock			$ 103,600,000	$ 107,600,000		$ 156,900,000
Over-Allotment Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)		975,000		882,352		550,806
Share price (in dollars per share)		$ 17
Proceeds from issuance of common stock		$ 15,600,000
At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)								0		687,189		1,802,651
Proceeds from issuance of common stock										$ 10,900,000		$ 38,200,000
Stock issuance sales agreement, authorized offering price, maximum					$ 125,000,000		$ 75,000,000	$ 125,000,000
Sale of stock, issuance costs, commission, percentage, maximum					3.00%		3.00%	3.00%
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for purchase under common stock warrants (in shares)	34,113		34,113					0		34,113	34,113
Shares issued upon exercise of warrant (shares)	11,134
Issuance of common stock in connection with At-The-Market offering, net of issuance costs (in shares)								975,000	6,764,705	687,189		1,802,651
Share-based Payment Arrangement | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)								765,675
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)										1,640,275	373,500	435,525
Restricted Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)								1,261,225		1,640,275
Performance-based Common Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)								215,000		865,000
Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares underlying stock options granted (in shares)								0
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)			1,404,005							1,404,005
Employee Stock [Member] | 2014 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)								1,704,005
Weighted Average | At the Market Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)			$ 15.82			$ 22.17				$ 15.82		$ 22.17
Weighted Average | Outstanding common stock warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights			$ 14.95							$ 14.95

Stockholders' Equity and Stoc_4

Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Convertible senior notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	8,878,938	0
Outstanding common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	5,305,185	4,372,676
Restricted Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	2,799,982	768,770
Shares of common stock expected to be purchased on June 30 under the 2014 ESPP
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	49,861	35,619
Outstanding common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	0	34,113	34,113	34,113	34,113

Stockholders' Equity and Stoc_5

Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	$ 6,544	$ 4,159	$ 17,922	$ 16,273	$ 13,230
Research and Development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	2,442	2,079	8,512	7,480	5,902
General and Administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	$ 4,102	$ 2,080	$ 9,410	$ 8,793	$ 7,328

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Convertible debt, fair value disclosures	$ 229,500
Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value, beginning balance	2,952	$ 2,753
Change in fair value	90	199
Fair value, ending balance	$ 3,042	$ 2,952

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2020	Mar. 31, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Loss Contingencies [Line Items]
Accrued milestone obligations				$ 1,000,000	$ 1,000,000
Indemnification liability recorded during the period			$ 0
Teoxane Agreement
Loss Contingencies [Line Items]
Collaborative agreement, contractual period	10 years	10 years
Collaborative agreement, extended contractual period	2 years	2 years
Fair value of assets acquired	$ 43,500,000
List Laboratories | Product Approval Payment Derivative
Loss Contingencies [Line Items]
Accrued milestone obligations		$ 2,000,000		2,000,000
Botulinum Toxin Research Associates, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations		16,000,000		16,000,000
BioSentinel, Inc.
Loss Contingencies [Line Items]
Accrued milestone obligations		300,000		300,000
Accruals and Other Current Liabilities
Loss Contingencies [Line Items]
Fair value of assets acquired		$ 1,000,000		1,000,000
Service Agreements | Ajinomoto Althea, Inc.
Loss Contingencies [Line Items]
Prepaid purchase obligations				$ 1,500,000

The Company and Basis of Presen

The Company and Basis of Presentation - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended									12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net loss	$ 61,933	$ 45,326	$ 41,409	$ 37,390	$ 35,304	$ 40,616	$ 32,834	$ 34,080	$ 35,037	$ 159,429	$ 142,568	$ 120,587
Working capital surplus	476,800	255,600								255,600
Cash, cash equivalents, and short-term investments	511,300	290,100								290,100
Accumulated deficit	$ 906,137	$ 844,204				$ 684,775				$ 844,204	$ 684,775
Cash and cash equivalents, and investments, expected funding term for operating plan (in months)	12 months									12 months

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)segmentshares	Dec. 31, 2019USD ($)segmentshares	Mar. 31, 2019shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)shares
Property, Plant and Equipment [Line Items]
Number of Operating Segments | segment	1	1
Restricted cash		$ 700			$ 700
Restricted cash, balance to remain until end of lease		$ 500
Common stock, shares outstanding (in shares) | shares	57,026,154	52,374,735	44,004,658		36,975,203
Total right-of-use asset	$ 25,961	$ 26,531		$ 24,700	$ 0
Present value of operating lease payments	$ 28,517	29,340		$ 28,200
Deferred rent liabilities		3,500
Letter of Credit
Property, Plant and Equipment [Line Items]
Restricted cash		$ 200
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated useful life		3 years
Lab equipment and furniture and fixtures
Property, Plant and Equipment [Line Items]
Estimated useful life		5 years
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Estimated useful life		7 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Estimated useful life		15 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Antidilutive Securities (Details) - shares	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)			4,734,616	3,605,333	3,210,400
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)	0	34,113	34,113	34,113	34,113
Unvested restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)			1,808,518	605,012	639,287

Revenue (Details)

Revenue (Details) - USD ($)	Feb. 28, 2018	Mar. 31, 2020	Jan. 31, 2019	Dec. 31, 2018	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Aug. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue maximum for receipt of tiered milestone payments														$ 1,000,000
Revenue					$ 58,000	$ 89,000	$ 46,000	$ 0	$ 278,000	$ 487,000	$ 2,362,000	$ 686,000	$ 193,000	413,000	$ 3,729,000	$ 262,000
Remaining performance obligation		$ 31,000,000			31,000,000	31,000,000								31,000,000
Deferred revenue, current portion		10,079,000		$ 8,588,000	10,079,000	7,911,000				8,588,000				7,911,000	8,588,000
Deferred revenue, net of current portion		46,722,000		42,684,000	46,722,000	47,948,000				42,684,000				47,948,000	42,684,000
Development Services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue					100,000				300,000					400,000	3,700,000
Deferred revenue, current portion		10,100,000		8,600,000	10,100,000	7,900,000				8,600,000				7,900,000	8,600,000
Deferred revenue, net of current portion		15,700,000		$ 12,700,000	15,700,000	18,000,000				$ 12,700,000				18,000,000	$ 12,700,000
Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contingent payments receivable, maximum			$ 230,500,000			230,500,000								230,500,000
Deferred revenue, net of current portion						30,000,000								30,000,000
Non-refundable upfront payment receivable		1,000,000	30,000,000		1,000,000	30,000,000								30,000,000
Contractual period for payment of non-refundable upfront payment				30 days
Foreign withholding tax, amount		100,000	$ 3,000,000
Contractual period for entering into sub-agreements				6 months
Finite-lived intangible asset, useful life				2 years
Termination notice requirement				120 days
Revenue														0
Contract with customer, liability, revenue recognized					0				$ 0
Mylan Ireland Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment	$ 30,000,000
Contingent payments receivable, maximum	100,000,000
Revenue maximum for receipt of tiered milestone payments	225,000,000
Contract with customer, asset, gross, current																	$ 5,000,000
Annual sales threshold for earning royalties during the first four years after commercialization	50,000,000
Initial estimated transaction price	81,000,000
Remaining performance obligation		$ 106,800,000			$ 106,800,000	$ 106,900,000								$ 106,900,000
Mylan Ireland Limited | Scenario, Previously Reported [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable upfront payment	25,000,000
Development Milestones | Mylan Ireland Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue maximum for receipt of tiered milestone payments	$ 40,000,000

Derivative Liability - Addition

Derivative Liability - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Settlement And Termination [Line Items]
Nonrecurring milestone payment		$ 1,000	$ 1,000
Medicis Pharmaceutical Corporation
Settlement And Termination [Line Items]
Gain (loss) on derivative liability due to remeasurement		(200)	(100)	$ (600)
Medicis Pharmaceutical Corporation | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Fair value of derivative	$ 3,000	3,000	$ 2,700
Valeant Pharmaceuticals International, Inc. | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Nonrecurring milestone payment	$ 4,000	$ 4,000
Measurement Input, Expected Term | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Fair value, measurement input, duration	8 months 12 days	10 months 24 days	1 year 6 months
Measurement Input, Entity Credit Risk | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	7.50%	7.50%	8.00%
Measurement Input, Risk Free Interest Rate | Medicis Pharmaceutical Corporation | Product Approval Payment Derivative
Settlement And Termination [Line Items]
Fair value, measurement input (percent)	0.20%	1.60%	2.60%

Cash Equivalents and Investment

Cash Equivalents and Investments (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Cost	$ 509,109,000	$ 282,683,000	$ 171,784,000
Gross unrealized gain	524,000	8,000	5,000
Gross unrealized loss		(5,000)	(13,000)
Fair Value	509,633,000	282,686,000	171,776,000
Short-term investments	224,621,000	118,955,000	102,556,000
Other-than-temporary impairments on available-for-sale securities	0	0	0
Money market funds
Debt Securities, Available-for-sale [Line Items]
Cost	179,031,000	136,258,000	38,354,000
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	179,031,000	136,258,000	38,354,000
U.S. treasury securities
Debt Securities, Available-for-sale [Line Items]
Cost	30,124,000	48,349,000	80,844,000
Gross unrealized gain	182,000	6,000	5,000
Gross unrealized loss		0	(5,000)
Fair Value	30,306,000	48,355,000	80,844,000
U.S. government agency obligations
Debt Securities, Available-for-sale [Line Items]
Cost	159,634,000	5,993,000	52,586,000
Gross unrealized gain	342,000	2,000	0
Gross unrealized loss		(5,000)	(8,000)
Fair Value	159,976,000	5,990,000	52,578,000
Commercial paper
Debt Securities, Available-for-sale [Line Items]
Cost	140,320,000	77,082,000	0
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	140,320,000	77,082,000	0
Overnight repurchase agreements
Debt Securities, Available-for-sale [Line Items]
Cost	0	15,001,000	0
Gross unrealized gain	0	0	0
Gross unrealized loss		0	0
Fair Value	0	15,001,000	0
Cash equivalents
Debt Securities, Available-for-sale [Line Items]
Fair Value	$ 285,012,000	$ 163,731,000	$ 69,220,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		$ 184,613	$ 119,198
Total liabilities measured at fair value		0	0
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		136,258	38,354
Level 1 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		48,355	80,844
Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 1 | Overnight repurchase agreements
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 1 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 1 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value		0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		98,073	52,578
Total liabilities measured at fair value		0	0
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 2 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		77,082
Level 2 | Overnight repurchase agreements
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		15,001
Level 2 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		5,990	52,578
Level 2 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value		0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Total liabilities measured at fair value		2,952	2,753
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 3 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 3 | Overnight repurchase agreements
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0
Level 3 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		0	0
Level 3 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value		2,952	2,753
Recurring
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 509,633	282,686	171,776
Total liabilities measured at fair value	3,042	2,952	2,753
Recurring | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	179,031	136,258	38,354
Recurring | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	30,306	48,355	80,844
Recurring | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	140,320	77,082
Recurring | Overnight repurchase agreements
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		15,001
Recurring | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	159,976	5,990	52,578
Recurring | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	3,042	2,952	$ 2,753
Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	209,337
Total liabilities measured at fair value	0	0
Recurring | Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	179,031
Recurring | Level 1 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	30,306
Recurring | Level 1 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 1 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 1 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	300,296
Total liabilities measured at fair value	0	0
Recurring | Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 2 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 2 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	140,320
Recurring | Level 2 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	159,976
Recurring | Level 2 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	0	0
Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Total liabilities measured at fair value	3,042	2,952
Recurring | Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 3 | U.S. treasury securities
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 3 | Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 3 | U.S. government agency obligations
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	0
Recurring | Level 3 | Derivative liability
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total liabilities measured at fair value	$ 3,042	$ 2,952

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 31,621	$ 28,421
Less: Accumulated depreciation		(16,866)	(13,972)
Property and equipment, net	$ 13,967	14,755	14,449
Manufacturing equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross		19,113	11,307
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross		5,374	4,752
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross		2,386	8,925
Computer software
Property, Plant and Equipment [Line Items]
Property and equipment, gross		2,040	1,299
Computer equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross		1,505	1,351
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, gross		$ 1,203	$ 787

Balance Sheet Components - Sc_2

Balance Sheet Components - Schedule of Accruals and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Balance Sheet Components [Abstract]
Compensation		$ 7,933	$ 6,743
Clinical trials		4,746	4,021
Professional service		2,732	2,272
Nonrecurring milestone payment		1,000	1,000
Manufacturing and quality control		1,798	260
Property and equipment (including construction in progress)		221	111
Other current liabilities		206	541
Total accruals and other current liabilities	$ 16,178	18,636	14,948
Bonus accruals		$ 5,500	$ 5,300

Leases - Operating Lease Paymen

Leases - Operating Lease Payments under ASC 840 (Details) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 5,826
2020	6,011
2021	6,196
2022	4,696
2023 and thereafter	20,173
Total payments	$ 42,902

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Plan - Additional Information (Details)	Jan. 01, 2015	Aug. 26, 2014	Jan. 31, 2020shares	Mar. 31, 2020USD ($)shares	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)equity_compensation_plan$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jan. 01, 2020shares	Dec. 31, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity compensation plans | equity_compensation_plan						3
Share-based compensation arrangement by share-based payment award, equity Instruments other than options, outstanding, weighted average remaining contractual terms						10 years
Unrecognized compensation cost | $						$ (18,487,000)	$ (20,202,000)
Performance stock awards, weighted average grant date fair value (in dollar per share) | $ / shares						$ 10.78
Stock options granted (in shares)						1,976,750	1,136,650	960,525
Employee service share based compensation nonvested awards total compensation cost not yet recognized restricted stock awards | $						$ 11,891,000	$ 10,591,000
Weighted average exercise price per share, nonemployee stock | $ / shares						$ 14.53	$ 28.30	$ 21.75
Stock-based compensation | $				$ 6,544,000	$ 4,159,000	$ 17,922,000	$ 16,273,000	$ 13,230,000
Employee service share based compensation nonvested awards total compensation cost not yet recognized performance stock awards | $						$ 8,839,000	$ 0
2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant, additional shares reserved						300,000
Percentage of outstanding stock	4.00%
Common stock, capital shares reserved for future issuance (in shares)				929,364		641,813			2,094,989
Unrecognized compensation cost | $						$ (1,976,750)
2014 Equity Incentive Plan | Scenario, Previously Reported [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)									1,479,008
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)				246,130		174,546
Restricted stock awards granted (in shares)						0
Stock options granted (in shares)						0
Share price (in dollars per share) | $ / shares						$ 16.23	$ 20.13	$ 35.75
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted (in shares)						1,640,275	373,500	435,525
Restricted Stock Awards | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted (in shares)				1,261,225		1,640,275
Performance-based Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested (shares)						865,000
Employee benefits and share-based compensation | $						$ 500,000
Performance-based Common Stock | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted (in shares)				215,000		865,000
Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted (in shares)				0
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant, additional shares reserved						300,000
Percentage of outstanding stock	1.00%
Common stock, capital shares reserved for future issuance (in shares)						1,404,005
Share-based compensation arrangement by share-based payment award, shares issued in period						74,935
Vesting Period 1 | Restricted Stock Awards | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		1 year
Vesting Period 1 | Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage		25.00%
Vesting Period 2 | Restricted Stock Awards | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		3 years
Vesting Period 3 | Restricted Stock Awards | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		4 years
1/36th of the Remaining Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by share based payment award remaining vesting rights percentage						2.78%
1/48th of the Remaining Grant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by share based payment award remaining vesting rights percentage						2.08%
Weighted Average | Employee Stock Option | 2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period		4 years
Subsequent Event | 2014 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)									2,094,989
Restricted stock awards granted (in shares)			1,027,825
Stock options granted (in shares)			568,675
Unvested restricted stock awards | Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested (shares)						1,808,518	605,012	639,287		416,229

Stock-Based Compensation - St_2

Stock-Based Compensation - Stock Option Plan - Summary of Stock Option and Restricted Stock Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares Available for Grant [Roll Forward]
Number of shares available for grant, grants in period		1,976,750	1,136,650	960,525
Number of shares underlying outstanding options, cancelled/forfeited		(837,332)	(448,617)	(231,430)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares underlying outstanding options, beginning balance	4,734,616	3,605,333	3,210,400	2,790,646
Number of shares available for grant, grants in period		1,976,750	1,136,650	960,525
Number of shares underlying outstanding options, exercises		(10,135)	(293,100)	(309,341)
Number of shares underlying outstanding options, cancelled/forfeited		(837,332)	(448,617)	(231,430)
Number of shares underlying outstanding options, ending balance		4,734,616	3,605,333	3,210,400
Number of shares underlying outstanding options, exercisable		2,659,741
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price per share, beginning balance	$ 19.34	$ 22.66	$ 20.41	$ 19.31
Weighted average exercise price per share, granted		14.53	28.30	21.75
Weighted average exercise price per share, exercised		11.76	15.45	12.88
Weighted average exercise price per share, cancelled/forfeited		22.40	25.59	22.76
Weighted average exercise price per share, ending balance		19.34	22.66	20.41
Weighted average exercise price per share, exercisable		21.31
Granted (in dollars per share)		$ 8.29	$ 16.35	$ 13.59
Weighted average remaining contractual life, outstanding		6 years 2 months 12 days
Weighted average remaining contractual life, exercisable		3 years 10 months 24 days
Aggregate intrinsic value, exercised		$ 45	$ 1,519	$ 7,073
Aggregate intrinsic value, outstanding		7,762
Aggregate intrinsic value, exercisable		$ 3,433
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares Available for Grant [Roll Forward]
Forfeited (in shares)		(192,731)	(172,468)	(81,905)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Restricted stock awards granted (in shares)		1,640,275	373,500	435,525
Restricted stock units, forfeited (in shares)		(192,731)	(172,468)	(81,905)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Granted (in dollars per share)		$ 12.78	$ 28.37	$ 22.08
2014 Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (in dollars per share)		$ 16.23	$ 20.13	$ 35.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares Available for Grant [Roll Forward]
Number of shares available for grant, grants in period		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares available for grant, grants in period		0
Restricted stock awards granted (in shares)		0
2014 Inducement Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares Available for Grant [Roll Forward]
Number of shares available for grant, grants in period	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares available for grant, grants in period	0
2014 Equity Incentive Plan | Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Restricted stock awards granted (in shares)	1,261,225	1,640,275

Stock-Based Compensation - St_3

Stock-Based Compensation - Stock Option Plan - Summary of Restricted Stock Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Granted (in dollars per share)	$ 8.29	$ 16.35	$ 13.59
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Granted (in shares)	1,640,275	373,500	435,525
Vested (in shares)	(244,038)	(235,307)	(130,562)
Forfeited (in shares)	(192,731)	(172,468)	(81,905)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Outstanding, beginning balance (in dollars per share)	$ 24.61	$ 20.86	$ 20.02
Granted (in dollars per share)	12.78	28.37	22.08
Vested (in dollars per share)	23.80	20.25	23.25
Forfeited (in dollars per share)	21.47	24.83	19.32
Outstanding, ending balance (in dollars per share)	$ 14.32	$ 24.61	$ 20.86
Unvested restricted stock awards | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Outstanding, beginning balance (in shares)	605,012	639,287	416,229
Outstanding, ending balance (in shares)	1,808,518	605,012	639,287

Stock-Based Compensation - St_4

Stock-Based Compensation - Stock Option Plan - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining contractual term (in years)	6 years 10 days
Expected volatility	60.20%
Risk-free interest rate	2.10%
Expected dividend rate	0.00%
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining contractual term (in years)		6 years	6 years
Expected volatility		60.20%	67.70%
Risk-free interest rate		2.70%	2.10%
Expected dividend rate		0.00%	0.00%
Monte Carlo Simulation Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining contractual term (in years)	10 years
Expected volatility	60.00%
Risk-free interest rate	1.80%
Expected dividend rate	0.00%
2014 ESPP | Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining contractual term (in years)	6 months	6 months	6 months
Expected volatility	43.40%	50.90%	59.20%
Risk-free interest rate	2.30%	1.90%	0.90%
Expected dividend rate	0.00%	0.00%	0.00%

Stock-Based Compensation - St_5

Stock-Based Compensation - Stock Option Plan - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	$ 6,544	$ 4,159	$ 17,922	$ 16,273	$ 13,230
Research and Development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	2,442	2,079	8,512	7,480	5,902
General and Administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock based compensation expense	$ 4,102	$ 2,080	$ 9,410	$ 8,793	$ 7,328

Stock-Based Compensation - Comm

Stock-Based Compensation - Common Stock (Details) - $ / shares	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Common stock, shares authorized (in shares)	95,000,000	95,000,000	95,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock subject to repurchase (in shares)			0
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)			95,000,000
Common stock, par value (in dollars per share)			$ 0.001
2014 Inducement Plan
Class of Stock [Line Items]
Share price (in dollars per share)		$ 16.23	$ 20.13	$ 35.75

Stock-Based Compensation Unreco

Stock-Based Compensation Unrecognized Compensation Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Unrecognized Compensation Cost
Unrecognized compensation cost	$ 18,487	$ 20,202
Employee service share based compensation nonvested awards total compensation cost not yet recognized performance stock awards	8,839	0
Employee service share based compensation nonvested awards total compensation cost not yet recognized restricted stock awards	11,891	10,591
Employee service share based compensation nonvested awards total compensation cost not yet recognized total unrecognized compensation cost	$ 39,217	$ 30,793
Weighted Average Expected Recognize Period
Share-based compensation arrangement by share-based payment award, options, vested and expected to vest, outstanding, weighted average remaining contractual term	2 years 10 months 24 days	2 years 8 months 12 days
Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding weighted average remaining contractual term1 restricted stock awards	2 years 3 months 18 days	2 years 4 months 24 days
Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding weighted average remaining contractual term1 performance stock awards	2 years 4 months 24 days	0 years
Sharebased compensation arrangement by sharebased payment award options vested and expected to vest outstanding weighted average remaining contractual term1 total unrecognized compensation cost	2 years 7 months 6 days	2 years 7 months 6 days

Stock-Based Compensation Stock

Stock-Based Compensation Stock Option Plan - Granted to Non-employee Consultants (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 10 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	60.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		6 years	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		60.20%	67.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.70%	2.10%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%
Non-employee Consultants | Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years 6 months	8 years 10 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		59.40%	67.90%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.80%	2.30%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	1 Months Ended						3 Months Ended		12 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Jan. 31, 2019	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2016	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Feb. 29, 2020
Class of Stock [Line Items]
Proceeds from issuance of common stock									$ 10,870,000	$ 0	$ 38,760,000
Common Stock
Class of Stock [Line Items]
Common stock warrants outstanding (in shares)		34,113					0		34,113	34,113		34,113
Issuance of common stock in connection with offerings (in shares)							975,000	6,764,705	687,189		1,802,651
Warrants | Weighted Average
Class of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights		$ 14.95							$ 14.95
Follow on Public Offering
Class of Stock [Line Items]
Issuance of common stock in connection with offerings (in shares)		6,500,000	6,764,705		5,389,515
Proceeds from issuance of common stock		$ 103,600,000	$ 107,600,000		$ 156,900,000
Share price (in dollars per share)		$ 17	$ 17		$ 31				$ 17		$ 31
Over-Allotment Option
Class of Stock [Line Items]
Issuance of common stock in connection with offerings (in shares)	975,000		882,352		550,806
Proceeds from issuance of common stock	$ 15,600,000
Share price (in dollars per share)	$ 17
At the Market Offering
Class of Stock [Line Items]
Issuance of common stock in connection with offerings (in shares)							0		687,189		1,802,651
Proceeds from issuance of common stock									$ 10,900,000		$ 38,200,000
Stock issuance sales agreement, authorized offering price, maximum				$ 125,000,000		$ 75,000,000	$ 125,000,000
Sale of stock, issuance costs, commission, percentage, maximum				3.00%		3.00%	3.00%
At the Market Offering | Weighted Average
Class of Stock [Line Items]
Share price (in dollars per share)		$ 15.82			$ 22.17				$ 15.82		$ 22.17
Subsequent Event | Over-Allotment Option
Class of Stock [Line Items]
Issuance of common stock in connection with offerings (in shares)	975,000
Proceeds from issuance of common stock	$ 15,600,000

Income Taxes - Components of Ne

Income Taxes - Components of Net Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Domestic			$ (159,429)	$ (139,568)	$ (118,331)
Foreign			0	0	(2,256)
Loss before income taxes	$ (61,833)	$ (35,304)	$ (159,429)	$ (139,568)	$ (120,587)

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Assets (Liabilities)
Net operating loss carryforward	$ 184,879	$ 146,618
Accruals and reserves	1,537	2,191
Stock-based compensation	6,241	5,173
Tax credits	17,449	12,230
Fixed and intangible assets	2,803	3,328
Deferred revenue	10,703	0
Operating lease liabilities	6,174
Other	19	0
Total deferred tax assets	229,805	169,540
Less: valuation allowance	(224,222)	(169,540)
Deferred tax assets, gross	5,583	0
Operating lease right of use assets	(5,583)
Deferred tax assets, net	0	$ 0
Increase in valuation allowance	$ (54,700)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Oct. 31, 2017	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax Contingency [Line Items]
Impact of the tax reform act			$ 0	$ 5,154,000	$ 62,903,000
Adjustment to valuation allowance for change in deferred tax assets			(68,100,000)
Unrecognized tax benefits			5,698,000	$ 4,200,000	$ 2,577,000	$ 1,819,000
Liability for uncertain tax positions			0
Increase in deferred tax assets		$ 15,000,000
Orphan drug credit carryforward
Income Tax Contingency [Line Items]
Tax credit carryforwards			7,700,000
Federal
Income Tax Contingency [Line Items]
NOL carryforwards			$ 734,600,000
Tax year NOL carryforwards begin to expire			Dec. 31, 2020
Federal | Research and development tax credits
Income Tax Contingency [Line Items]
Tax credit carryforwards			$ 9,100,000
Tax year credit carryforwards begin to expire			Dec. 31, 2023
Federal | Orphan drug credit carryforward
Income Tax Contingency [Line Items]
Tax year credit carryforwards begin to expire			Dec. 31, 2038
California
Income Tax Contingency [Line Items]
NOL carryforwards			$ 398,200,000
Tax year NOL carryforwards begin to expire			Dec. 31, 2028
California | Research and development tax credits
Income Tax Contingency [Line Items]
Tax credit carryforwards			$ 7,600,000
Other States
Income Tax Contingency [Line Items]
NOL carryforwards			$ 281,700,000
Tax year NOL carryforwards begin to expire			Dec. 31, 2030
CALIFORNIA
Income Tax Contingency [Line Items]
Increase in NOL due to change in apportionment model		$ 219,000,000
Revance International Limited | Intellectual Property
Income Tax Contingency [Line Items]
Transfer of economic rights to intellectual property	$ 41,200,000
Accounting Standards Update 2018-05
Income Tax Contingency [Line Items]
Impact on deferred taxes			$ 68,100,000

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%	35.00%
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Tax benefit at statutory federal rate	$ (33,480)	$ (29,309)	$ (40,999)
Research and development credits	(4,723)	(4,064)	(1,858)
Other changes in valuation allowance	36,379	42,902	(35,783)
Nondeductible/nontaxable items	1,429	108	738
Other	395	(153)	224
Sale of intellectual property	0	(14,008)	14,008
Foreign rate differential and withholding taxes	0	2,370	767
Impact of the Tax Reform Act	0	5,154	62,903
Income tax provision	$ 0	$ 3,000	$ 0

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance	$ 4,200	$ 2,577	$ 1,819
Additions for prior tax positions	0	333	0
Additions for current tax positions	1,498	1,290	758
Balance	$ 5,698	$ 4,200	$ 2,577

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - USD ($)	Feb. 14, 2020	Jan. 31, 2020	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	May 28, 2020
Subsequent Event [Line Items]
Stock options granted (in shares)				1,976,750	1,136,650	960,525
2014 Equity Incentive Plan | Subsequent Event
Subsequent Event [Line Items]
Stock options granted (in shares)		568,675
Restricted stock awards granted (in shares)		1,027,825
Mylan Ireland Limited | Subsequent Event
Subsequent Event [Line Items]
One-time cash milestone payment that counterparty is obligated to pay							$ 30,000,000
Senior Unsecured Obligations | Subsequent Event
Subsequent Event [Line Items]
Principal amount of notes	$ 287,500,000
Stated interest rate (percent)	1.75%
Net proceeds from issuance of senior unsecured debt obligations	$ 278,400,000
Sinking fund amount	0
Debt proceeds used to pay the cost of certain capped call transactions	$ 28,900,000
Teoxane Agreement
Subsequent Event [Line Items]
Issuance of common stock in connection with the Teoxane Agreement (in shares)		2,500,000
Collaborative agreement, contractual period		10 years	10 years
Teoxane Agreement | Subsequent Event
Subsequent Event [Line Items]
Issuance of common stock in connection with the Teoxane Agreement (in shares)		2,500,000
Collaborative agreement, contractual period		10 years
Contractual extension period		2 years

Quarterly Results of Operatio_3

Quarterly Results of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Quarterly Financial Data [Abstract]
Revenue	$ 58	$ 89	$ 46	$ 0	$ 278	$ 487	$ 2,362	$ 686	$ 193	$ 413	$ 3,729	$ 262
Loss from operations	(60,960)	(46,170)	(42,540)	(39,122)	(36,627)	(38,412)	(33,641)	(34,919)	(35,662)	(164,459)	(142,634)	(120,424)
Net loss	(61,933)	(45,326)	(41,409)	(37,390)	(35,304)	(40,616)	(32,834)	(34,080)	(35,037)	(159,429)	(142,568)	(120,587)
Basic and diluted net loss	$ (61,933)	$ (45,326)	$ (41,409)	$ (37,390)	$ (35,304)	$ (40,616)	$ (32,834)	$ (34,080)	$ (35,037)	$ (159,429)	$ (142,568)	$ (120,587)
Basic and diluted net loss per share (in dollars per share)	$ (1.15)	$ (0.99)	$ (0.96)	$ (0.86)	$ (0.85)	$ (1.12)	$ (0.91)	$ (0.94)	$ (0.97)	$ (3.67)	$ (3.94)	$ (4.01)